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SUMMARY OF RELATIVE EFFECTIVENESS OF REGORAFENIB AS 
MONOTHERAPY FOR THE TREATMENT OF ADULT PATIENTS WITH 
HEPATOCELLULAR CARCINOMA WHO HAVE BEEN PREVIOUSLY 
TREATED WITH SORAFENIB 
Scope 
The scope can be found here: scope. 
Introduction 
Description of technology and comparators 
On 04 July 2017, the Committee for Medicinal Products for Human Use (CHMP) of the European 
Medicines Agency (EMA) adopted a positive opinion recommending the extension of indication for 
STIVARGA® (regorafenib) for the treatment of adult patients with hepatocellular carcinoma (HCC) 
who have been previously treated with sorafenib. Before this positive opinion was given, the Mar-
keting Authorisation Holder (MAH) of STIVARGA® (Bayer) requested EUnetHTA to perform an as-
sessment of the relative effectiveness and safety of regorafenib with this new indication. Regoraf-
enib is an oral antineoplastic agent that potently blocks the multiple protein kinases involved in 
tumour angiogenesis, oncogenesis and the tumour microenvironment. The addition of regorafenib 
to best supportive care (BSC) in HCC patients who have been previously treated with sorafenib 
aims to improve the overall survival (OS) in comparison with placebo plus BSC. 
 
Health problem 
HCC is the most common type of liver cancer. Its incidence varies from 3 out of 100,000 in western 
countries to more than 15 out of 100,000 in certain areas of the world. The largest risk factor for 
HCC, associated with 80-90% of all cases, is cirrhosis of various aetiologies: hepatitis C virus 
(HCV), hepatitis B virus (HBV), and chronic use of alcohol. Systemic treatment of HCC at an ad-
vanced stage depends on a patient’s general state. For patients with preserved liver functions and 
general state, treatment with sorafenib is generally recommended with the objective of increasing 
survival but not curing the disease. In the case of progression or intolerance to sorafenib, BSC is 
the preferred option as no antineoplastic treatment was approved or recommended in this situation 
until regorafenib was available. Therefore, the scoped population of this assessment faces an un-
met medical need. 
 
Methods 
The authors checked and validated an extensive and detailed literature search for the identification 
of the scientific evidence of regorafenib in HCC provided by the manufacturer. The systematic liter-
ature searches were performed in January 2017 with no time or language limits using the following 
databases: MEDLINE, EMBASE, the Cochrane Library, clinical trials registries and relevant confer-
ence websites. This systematic literature search was restricted to randomised controlled trials 
(phases II and III), review and meta-analysis (see Appendix 1 for details). The authors updated the 
literature search on 01 July 2017 using the same research strategy to check whether all relevant 
information was included in this relative effectiveness assessment (REA). The Cochrane risk of bias 
assessment was conducted on a study and outcomes level by the authors method was used to 
assess the quality of evidence (see Appendix 1). 
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Results (see table S.0.1) 
Available evidence 
Overall, the body of evidence selected for this REA came from a single pivotal, randomised, double-
blind, phase III trial sponsored by the MAH comparing regorafenib (160 mg by mouth once daily in 
a 3/1 schedule) plus BSC with placebo plus BSC in patients with HCC already treated with sorafenib 
(the RESORCE trial). 
 
Clinical effectiveness 
Overall, 573 patients were randomised in the RESORCE trial: 379 in the regorafenib plus BSC 
group and 194 in the placebo plus BSC group. The population included in this trial was notably 
restricted to those who tolerated sorafenib treatment defined as not less than 20 days at a minimum 
daily dose of 400 mg once daily within the last 28 days prior to withdrawal, with a Child-Pugh score 
of A and a preserved general state. Demographic and baseline disease characteristics were bal-
anced across both treatment arms. This study met its primary endpoint: OS median OS time was 
10.6 months in the regorafenib group and 7.8 months in the placebo group, corresponding to an 
absolute gain of 2.8 months in favour of regorafenib with a hazard ratio (HR) of 0.627 (95% confi-
dence interval [CI] 0.500, 0.785), p=0.000020. The addition of regorafenib to BSC also induced an 
improvement in median progression free survival (PFS) from 1.5 months to 3.1 months: HR=0.455 
(95% CI 0.371, 0.558), p<0.000001; absolute gain =1.6 months. Data from the RESORCE trial sug-
gested the absence of a clinically relevant difference between the two groups in terms of health-
related quality of life (HRQoL) as measured by the following scales: EuroQoL five dimensions ques-
tionnaire (EQ-5D) and Functional Assessment of Cancer Therapy-Hepatobiliary questionnaire 
(FACT-hep). 
Safety 
More Grade ≥3 drug-related adverse events (AEs) were seen in the regorafenib group (51.9%) than 
in the placebo group (17.6%); similarly, drug-related serious adverse event (SAE) rates were higher 
in the regorafenib group (10.4%) than in the placebo group (2.6%). Drug-related AEs leading to the 
permanent discontinuation of study drug were also greater higher in the regorafenib group (10.4%) 
than in the placebo group (3.6%). 
The most frequent drug-related Grade 3 AEs in the regorafenib group were: hypertension (12.8%), 
hand–foot skin reaction (HFSR, 12.3%), blood bilirubin increased (5.1%), aspartate transaminase 
(AST) increased (4.5%) and hypophosphataemia (4.3%). 
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Table S.0.1: Summary of clinical effectiveness and safety evidence 
Outcome  
Anticipated absolute effects (95% CI) 
 
Relative effect 
(95% CI) 
Number of participants  
(number of studies) 
Overall judgment Risk 
of bias – outcome 
level 
Comments 
Results with 
placebo + BSC 
Results with 
regorafenib + BSC 
OS Median OS: 
7.8 months (95% CI 
6.3, 8.8) 
Median OS: 
10.6 months (95% CI 
9.1, 12.1) 
HR=0.627 (95% CI 
0.500, 0.785) 
 p =0.000020 
573 (1) Lowa Critical 
outcome 
PFS (mRECIST) Median PFS: 
1.5 months (95% CI 
1.4, 1.6) 
Median PFS: 
3.1 months (95% CI 
2.8, 4.2) 
HR=0.455 (95% CI 
0.371, 0.558) 
p<0.000001 
573 (1) Higha Important 
outcome 
HRQoL (EQ-5D index) 
Results expressed as LSM 
time-adjusted (AUC) 
0.77 [0.75; 0.79] 0.76 [0.75; 0.78] Difference: -0.01 
[-0.03; 0.02] 
573 (1) 
Evaluable population (at 
the end of the treatment: 
N=110/194 in the placebo 
group 
N=178/379 in the 
regorafenib group  
High a Critical 
outcome 
HRQoL (EQ-5D VAS) 
Results expressed as LSM 
time-adjusted AUC 
73.45 [71.84; 75.06] 71.68 [70.46; 72.90] Difference: -
1.77 -3.58; 0.04] 
573 (1) 
Evaluable population (at 
the end of the treatment: 
N=110/194 in the placebo 
group 
N=180/379 in the 
regorafenib group 
High a Critical 
outcome 
HRQoL (FACT-hep) 
Results expressed as LSM 
time-adjusted AUC 
133.17 [131.21; 
135.12] 
129.31 [127.84; 
130.79] 
Difference: -3.85 
[-6.06; -1.65] 
573 (1) 
Evaluable population (at 
the end of the treatment: 
N=111/194 in the placebo 
group 
Higha Critical 
outcome 
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Outcome  
Anticipated absolute effects (95% CI) 
 
Relative effect 
(95% CI) 
Number of participants  
(number of studies) 
Overall judgment Risk 
of bias – outcome 
level 
Comments 
Results with 
placebo + BSC 
Results with 
regorafenib + BSC 
N=178/379 in the 
regorafenib group 
Drug-related grade≥3 AEs 34 (17.6%) 194 (51.9%) NA 567 (1) Not applicable Critical 
outcome 
Drug-related SAEs 5 (2.6%) 39 (10.4%) NA 567 (1) Not applicable Critical 
outcome 
Drug-related permanent 
discontinuation due to AEs 
7 (3.6%) 39 (10.4%) NA 567 (1) Not applicable Critical 
outcome 
a see Appendix 1 for details. 
Abbreviations: AE=adverse event; AUC=area under the curve; BSC=best supportive care; CI=confidence interval; EQ-5D=EuroQoL five dimensions questionnaire; FACT-hep=functional assessment of 
cancer therapy questionnaire for patients with hepatobiliary cancer; HRQoL=health-related quality of life; LSM=least squares method; mRECIST=modified response evaluation criteria in solid tumors; 
NA=not applicable; OS=overall survival; PFS=progression free survival; SAE=serious adverse event; VAS=visual analogue scale. 
Source: clinical study report 
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Discussion 
This relative assessment is based on a single randomised, double-blind study (RESORCE). Over-
all, the design of the study is considered acceptable, with a low risk of bias, and the comparator is 
acceptable. No critical issue was found with the primary endpoint: OS. However, there is a high risk 
of bias in the assessment of the HRQoLs given the significant amount of missing data and the fact 
that the safety profile of regorafenib was associated with substantial side effects that might have 
compromised the blinding of the study. 
An evidence gap was identified in patients who did not tolerate sorafenib or had a deteriorated 
general state and liver function (ECOG >1; Child-Pugh score B) or both, as these patients, included 
in the scope population, were not eligible for the RESORCE study. 
 
Conclusion 
This extension of indication is based on a single randomised pivotal trial (the RESORCE study), 
which demonstrated that regorafenib plus BSC is more effective than placebo plus BSC in terms of 
OS in a selected population that tolerated sorafenib treatment and with a preserved general state 
(ECOG 0-1; Child-Pugh A). However, the addition of regorafenib to BSC induced a modest gain in 
terms of median OS (+2.8 months) that must be seen in view of the worsened safety profile, notably 
in terms of Grade ≥3 AEs, SAEs and AEs leading to dose modification or reduction. 
Given the poor prognosis of these patients and their general health status observed in clinical prac-
tice, HRQoL is also considered as a critical clinical endpoint. In view of the exploratory design of 
this endpoint, the conclusion on quality of life is greatly limited, which is regrettable. 
The stringent eligibility criteria of the RESORCE study result in the non-inclusion of a subset of 
patients, such as those who did not tolerate sorafenib or those with a deteriorated general health 
status (ECOG >1) or a Child-Pugh score of B or C, or a combination of these. Therefore, patients 
included in the RESORCE trial only partially reflect patients seen in clinical practice and the benefit 
of regorafenib cannot be assessed in these fragile populations. Further research or data collection 
are deemed necessary to evaluate the use of regorafenib in these specific subgroups. 
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1 SCOPE 
Descrip-
tion 
Project scope 
Popula-
tion  
 
Adult patients with hepatocellular carcinoma (HCC) who have been previously 
treated with sorafenib. 
International classification of diseases – version 10 (ICD-10): C22 
Medical subject heading (MeSH) term: carcinoma, hepatocellular 
Tree numbers: C04.588.274.623.160 
MeSH unique ID: D006528 
Interven-
tion  
 
Regorafenib 160 mg orally once daily for 21 consecutive days followed by 7 days off 
treatment (schedule 3/1) in combination with best supportive care (BSC) or palliative 
care. 
Regorafenib could be administered until: 
- Disease progression defined by modified response evaluation criteria in solid 
tumors (mRECIST); 
- Clinical progression, defined as an Eastern Cooperative Oncology Group 
(ECOG) performance score ≥3 or symptomatic deterioration, including in-
creased liver function tests; 
- Unacceptable toxicity. 
The regorafenib treatment could be continued beyond progression if the investigator 
judged that the patient would benefit from continued treatment. 
Compar-
ison 
 
Placebo in combination with BSC or palliative care. 
Out-
comes 
 
Efficacy:  
- Critical outcomes: overall survival (OS) and quality of life 
- Important outcome: progression-free survival (PFS) 
Safety:  
- Any adverse events (AEs) 
- Serious AEs (SAEs) 
- Grade ≥3 AEs 
- Grade 3 AEs 
- Grade 4 AEs 
- Grade 5 AEs 
- Discontinuation due to AEs 
- AEs of special interest (important risk identified in the Risk Management 
Plan). 
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2 METHODS AND EVIDENCE INCLUDED  
2.1 Assessment Team 
The workload was divided between the author and co-author: the author was responsible for the 
clinical effectiveness and safety domains and the co-author developed the domains concerning the 
description and technical characteristics of technology and the health problem and current use of 
the technology. 
The author checked the manufacturer’s literature review to verify that all updated and relevant stud-
ies and guidelines were included in the assessment. 
 
2.2 Source of assessment elements 
The selection of assessment elements was based on the EUnetHTA Core Model® Application for 
rapid effectiveness assessment (REA) [1]. Further assessment elements from the EUnetHTA Core 
Model® domains (ETH, ORG, SOC, LEG aspects – relevant for pharmaceuticals) were not included 
as they were not considered to be relevant for this REA [2]. The selected issues (generic questions) 
were translated into actual research questions (answerable questions). Some assessment element 
questions were answered together i.e., questions were listed below each other and a summarised 
answer was provided. 
 
2.3 Search 
The manufacturer presented the findings of an extensive and detailed literature search, identifying 
the scientific evidence for the use of regorafenib in HCC. The literature search strategy was checked 
and validated by the author. The reporting of the search followed the EUnetHTA guidelines and the 
requirements of the Preferred Reporting Items for Systematic Reviews and Meta-analyses Proto-
cols (PRISMA-P) statement.   
The systematic literature searches were performed by the Marketing Authorisation Holder (MAH) in 
January 2017, with no time or language limits, in the following databases (platform): 
- MEDLINE and EMBASE (ProQuest) 
- Cochrane Library, including Cochrane Database of Systematic Reviews (CDSR), Database 
of Abstracts of Reviews of Effects (DARE) and Cochrane Central Register of Controlled Trials 
(CENTER).  
- Relevant conference websites. 
- clinicaltrials.gov to identify planned, ongoing or completed studies that had not yet been pub-
lished. 
The inclusion and exclusion criteria that were applied by the MAH are provided in Table 2.1.  
Table 2.1: Inclusion and exclusion criteria for the systematic literature review 
Inclusion  
criteria 
Population: hepatocellular carcinoma (HCC) 
Intervention(s): regorafenib (STIVARGA®) 
Comparator(s): any 
Outcomes: overall survival (OS); time to progression (TTP); progression-free survival 
(PFS); objective response rate (ORR), disease control; treatment-emergent adverse 
events (TEAEs), serious adverse events (SAEs), patient reported outcome (PRO) / 
quality of life (QoL); all patient relevant endpoints 
Settings (if applicable): any 
Study design: randomised controlled trials (RCTs) including phase II and phase III, 
systematic literature reviews, meta-analysis 
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Language restrictions: none 
Other search limits or restrictions applied: none 
Exclusion  
criteria 
Population: other (oncology) indications not listed in the inclusion criteria 
Interventions: all interventions not listed in the inclusion criteria 
Comparator(s): NA 
Outcomes: NA 
Settings (if applicable): NA 
Study design: All other study designs not listed in the inclusion criteria 
Language restrictions: NA 
Other search limits or restrictions applied: NA 
 
Abbreviations: HCC=hepatocellular carcinoma; NA=not applicable; OS=overall survival; ORR=objective response rate; 
PFS=progression-free survival; PRO=patient reported outcome; QoL=quality of life; RCT=randomised controlled trial; 
SAE=serious adverse event; TEAE=treatment-emergent adverse event; TTP=time to progression. 
Source: MAH Submission file 
According to the MAH, the selection of articles (based on title/abstract and full text) was made by 
two reviewers implementing the screening process in parallel: 
- Both reviewers performed the titleabstract selection based on the inclusion and exclusion 
criteria (Table 2.1). The results of this selection were discussed by the reviewers and a se-
lection of articles made for the first review round. 
- The full text selection round followed the same process. If the reviewers could not agree on 
the selection of papers, a third reviewer (a senior team member) was consulted. 
The detailed search strategy is provided in Appendix 1. 
 
2.4 Study selection 
Through EMBASE, MEDLINE, Cochrane and conferences, a total of 330 records were identified 
(Figure 1). After removal of 7 duplicates, 323 records were screened. 
During the title and abstract selection process, a total of 302 records were excluded, mostly due to 
the population (n=153), the intervention (n=112), outcomes (n=36) and study design (n=1). The 
number of records eligible for full text selection was 21. From this batch, 11 publications were ex-
cluded because of their outcome (n=7) and study design (n=4), which were not in line with the 
established selection criteria (details in Appendix 1). Eventually, 10 records were included:  
- The first 4 records report on the outcomes of clinical trials. Only one of these records was a 
full study publication.  
- The last 6 of the 10 records consisted of reviews. No additional references were identified 
through screening the review references. 
The flow chart shown in Figure 2.1 illustrates the search and the process by which studies were 
selected for inclusion in the systematic review. 
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Figure 2.1: Flow chart 
Abbreviations: ESMO=European Society for Medical Oncology; RCT=randomised controlled trial 
Source: MAH Submission file 
In order to check whether all relevant evidence was up-to-date and included in the final report, the 
authors updated the literature search as of 01 July 2017 using the same research strategy. 
Through EMBASE, MEDLINE and Cochrane, a total of 58 records were identified. After removal of 
8 duplicates, 50 records were screened. 
During the title and abstract selection process, a total of 33 records were excluded, mostly due to 
the population (n=11), the intervention (n=7) and outcomes (n=15). The number of records eligible 
for full text selection was 17 of which:  
- 9 records reported on the outcomes of clinical trials; all were related to a single trial: the 
RESORCE study. 
- The last 8 of the 17 records consisted of reviews. No additional references were identified 
through screening the review references. 
Overall, no other relevant study was identified with this update. 
Records identified through 
database searching  
(n=219):  
- ProQuest: 217 
oEMBASE : 209 
oMEDLINE : 8 
- Cochrane : 2 
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Additional records identified through other sources 
(n=111) 
American Association for Cancer Research: 4 
American Society of Clinical Oncology: 1 
European Society for Medical Oncology: 4 
European Association for the Study of the Liver: 1 
ESMO World Congress on Gastrointestinal 
Cancer: 92 
Japanese Society of Medical Oncology: 3 
American Association for the Study of Liver 
Diseases: 3 
Records after duplicates removed  
(n = 323) 
Records screened 
(n=323) 
Records excluded 
(n=302) 
Full text articles assessed 
for eligibility  
(n = 21) 
Full-text articles excluded, with 
reasons  
(n=11) 
Exclusion criteria are: 
 Population (n=0) 
 Intervention/comparator (n=0) 
 Outcomes (n=7) 
 Study design (n = 4) 
Studies included in qualitative synthesis  
(n=10) 
RCTs (n=4 – publications related to 1 single 
RCT) 
review (n=6) 
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2.5 Data extraction and analyses 
Data used for the EFF and SAF part were extracted from the file submitted by the MAH and verified 
in the clinical study report (CSR) by the authors. No statistical analysis was performed for this REA. 
A meta-analysis was not possible as the assessment was based on a single pivotal trial and given 
the absence of comparators at this stage of the disease. 
  
2.6 Quality rating 
The single included study (the RESORCE trial) was assessed independently by the authors for 
methodological quality. The quality rating tool used was that applied by the Cochrane Collaboration 
(version 5.1.0; March 2011) for assessing risk of bias in randomised controlled trials (as recom-
mended by the EUnetHTA guideline on internal validity of randomised controlled trials [3]).  
This approach classifies risk of bias into 6 different domains:  
• Method used to generate the sequence of randomisation (random sequence generation); 
• Method used to mask the sequence of allocation to treatment (allocation concealment); 
• Measures used to ensure the ‘blindness’ of the study with respect to treatment assignment 
(blinding of participants, medical personnel and outcome assessors); 
• Completeness of the data for each outcome considered (incomplete outcome data); 
• Selective description of the results (selective outcome reporting); 
• Other sources of bias (e.g., bias due to the early interruption of the study because of the 
benefits without an appropriate stopping rule, use of a non-validated measurement instru-
ment, incorrect statistical analysis). 
 
For each domain, assessors were expected to judge the risk of bias (‘low risk’, ‘high risk’, or ‘un-
clear’) on the basis of the information retrieved from the paper and from the CSR. The results of the 
risk of bias assessment at both study and outcome level are presented in Table A8 and Table A9 
in Appendix 1. 
 
The external validity of the included trial was assessed using the EUnetHTA guideline on applica-
bility of evidence in the context of a relative effectiveness assessment of pharmaceuticals [4]), con-
sidering the following elements: population, intervention, comparator, outcomes and setting. 
 
The results of the external validity assessment are presented in Table A10 in Appendix 1. 
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2.7 Description of the evidence used 
Table 2.2: Main characteristics of study included 
Study 
name 
Study  
type 
Number 
of 
patients 
Intervention (s) Main  
endpoints 
Included in 
clinical 
effectiveness 
and/ or safety 
domain 
RESORCE 
trial 
Randomised 
(2:1 ratio), 
double-blind, 
placebo-
controlled, 
phase III trial  
573 Regorafenib 160 mg 
orally once daily for 
21 consecutive days 
followed by 7 days off 
treatment (schedule 3/1) 
in combination with best 
supportive care (BSC) 
or palliative care 
Vs placebo (schedule 
3/1) in combination with 
BSC or palliative care 
Primary 
endpoint: 
OS 
 
Secondary: 
PFS, ORR, 
QoL, safety 
Yes 
Abbreviations: BSC=best supportive care; ORR=overall response rate; OS=overall survival; PFS=progression-free 
survival; QoL=quality of life. 
Sources: clinical study report and MAH submission file. 
 
2.8 Deviations from project plan 
D0011, D0016 and D0017 were initially selected as relevant research questions in the project plan. 
During the assessment phase, however, the authors decided that these questions were not informa-
tive and decided not to include them in the final report. 
Due to time constraint, the grading of recommendations assessment, development and evaluation 
(GRADE) assessment was not performed by the authors. 
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3 DESCRIPTION AND TECHNICAL CHARACTERISTICS OF TECHNOLOGY 
(TEC)  
3.1 Research questions  
Element ID Research question 
B0001 What is regorafenib and the comparator(s)? 
A0020 For which indications has regorafenib received marketing authorisation? 
B0002 What is the claimed benefit of regorafenib in relation to the comparator(s)? 
B0003 What is the phase of development and implementation of regorafenib and the 
comparator(s)? 
A0021 What is the reimbursement status of regorafenib? 
 
3.2 Results 
Features of the technology and comparators 
B0001 – What is regorafenib and the comparator(s)? 
Regorafenib 
Regorafenib is an oral kinase inhibitor agent that targets a variety of kinases implicated in angio-
genic and tumour growth-promoting pathways. Regorafenib potentially targets angiogenic (includ-
ing the vascular endothelial growth factor [VEGF] receptors 1 to 3, and TIE2), stromal (mutated 
KIT), metastasis (VEGFR3, PDGFR, FGFR) and oncogenic receptor kinases (KIT, RET, RAF-1, 
BRAF, BRAFV600E). Its chemical structure is very similar to sorafenib, another oral kinase inhibitor. 
Regorafenib differs from sorafenib by the addition of one fluorine atom. 
Although regorafenib is a targeted therapy, there is no relevant predictive biomarker identified. 
 
Pharmacodynamics/Kinetics 
Absorption: a high-fat meal increased the mean area under the curve (AUC) of the drug by 48% 
compared with the fasted state and decreased the mean AUC of the active metabolites M-2 (N-
oxide) by 20% and M-5 (N-oxide and N-desmethyl) by 51%. 
 
A low-fat meal increased the mean AUC of regorafenib by 36%, M-2 by 40%, and M-5 by 23%, 
compared with the fasted state. 
 
Protein binding: the parent drug and its metabolites (M-2 and M-5) are highly protein bound (99.5% 
for the parent drug). 
 Metabolism: the parent drug is metabolised by the liver, via CYP3A4 and UGT1A9, primarily to its 
active metabolites M-2 and M-5. 
 
Bioavailability: the fraction of the administered dose of unchanged drug that reaches the systemic 
circulation is 69% for the tablets and 83% for the oral solution. 
 
Half-life elimination: regorafenib: 28 hours (range: 14–58 hours); M-2 metabolite: 25 hours (range: 
14–32 hours); M-5 metabolite: 51 hours (range: 32–70 hours) 
Time to peak: 4 hours 
Excretion: the drug is mainly excreted in the faeces (71%), 47% as parent drug and 24% as me-
tabolites; 19% of the drug is excreted in the urine.  
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Comparator(s) 
On 04 July 2017, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive 
opinion recommending the extension of indication for STIVARGA® (regorafenib) for the treatment 
of adult patients with HCC who have been previously treated with sorafenib. Currently, no active 
comparator for regorafenib is recommended or used in clinical practice for the treatment of patients 
with HCC who have been previously treated with sorafenib, and patients are commonly treated with 
BSC. BSC in cancer may include assessment and treatment of physical, psychological, social, and 
spiritual dimensions of suffering [5].  
Table 3.1 provides an overview of the technology. 
 
Table 3.1: Features of the intervention and comparators 
 Technology Comparator 
Non-proprietary name Regorafenib No active comparator is 
available 
Proprietary name STIVARGA® 
Active substance Regorafenib 
Galenic Form 40 mg film-coated tablets 
ATC code L01XE21 
Abbreviations: ATC=anatomical therapeutic chemical; EMA=European Medicines Agency. 
Source: EMA 2013. 
Administration and dosing of regorafenib is summarised in Table 3.2. 
 
Table 3.2: Administration and dosing of the intervention and comparators 
 Technology Comparator 
Administration mode Oral use 
It should be taken at the same time each day. The tablets should 
be swallowed whole with water after a light meal that contains less 
than 30% fat. An example of a light (low-fat) meal would include 1 
portion of cereal (about 30 g), 1 glass of skimmed milk, 1 slice of 
toast with jam, 1 glass of apple juice, and 1 cup of coffee or tea 
(520 calories, 2 g fat). 
No active 
comparator is 
available 
Description of 
packaging 
28 film-coated tablets in bottle 
84 film-coated tablets (3 x 28) in bottle 
 
Total volume 
contained in 
packaging for sale 
28-tablet package of 40 mg regorafenib formulation 
112-tablet package of 40 mg regorafenib formulation 
Dosing Recommended daily dose is 160 mg (4 tablets of 40 mg) taken 
once daily. 
Dose interruptions and/or dose reductions may be required based 
on individual safety and tolerability. Dose modifications are to be 
applied in 40 mg (1 tablet) steps. The lowest recommended daily 
dose is 80 mg. The maximum daily dose is 160 mg. 
 
Recommended 
duration of treatment 
3 weeks of daily regorafenib treatment followed by 1 week off 
treatment. This 4-week period is considered a treatment cycle. 
Treatment should continue as long as benefit is observed or until 
unacceptable toxicity occurs. 
Contraindications Hypersensitivity to the active substance or to any of the excipients 
Abbreviations: EMA=European Medicines Agency. 
Sources: manufacturer’s submission file; EMA 2013. 
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A0020 – For which indications has regorafenib received marketing authorisation?  
The approved indications of regorafenib (STIVARGA®) are: 
 Patients with metastatic colorectal cancer (mCRC) who have been previously treated with, 
or are not considered candidates for, available therapies. These include fluoropyrimidine-
based chemotherapy, an anti-VEGF therapy and an anti-epidermal growth factor receptor 
(EGFR) therapy (approved in the EU on 26 August 2013); 
 Unresectable or metastatic gastrointestinal stromal tumours (GIST) who progressed on or 
are intolerant to prior treatment with imatinib and sunitinib (approved in the EU on 
28 July 2017). 
 
On 04 July 2017, the CHMP adopted a positive opinion recommending the label extension of 
regorafenib, indicated as monotherapy for the treatment of adult patients with HCC who have been 
previously treated with sorafenib [6]. 
The aim of this report is to perform a relative assessment of the effectiveness and safety of regoraf-
enib in this new indication at the request of the MAH of STIVARGA®. 
 
B0002 – What is the claimed benefit of the regorafenib in relation to the comparator(s)? 
The addition of regorafenib to BSC in HCC patients who have been previously treated with sorafenib 
aims to improve the OS compared with placebo plus BSC. This claimed benefit is based on clinical 
data (the RESORCE trial) that is presented in Section 5. 
 
B0003 – What is the phase of development and implementation of regorafenib and the 
comparator(s)?  
As of 21 July 2017, regorafenib has regulatory approval in Ecuador, Japan, Korea, and the US for 
the treatment of adult patients with HCC who have been previously treated with sorafenib; see 
Table A11 in Appendix 2. 
 
A0021 – What is the reimbursement status of regorafenib? 
Reimbursement and pricing decisions are a national responsibility. Thus, the reimbursement status 
of regorafenib for HCC in different European Union (EU) countries will be decided at the national 
level after marketing authorisation validation by the European Commission. 
 
Detailed information on the reimbursement status and recommendations for regorafenib in other 
indications, as of 21 July 2017, are reported in Table A12 in Appendix 2. In summary, regorafenib 
is reimbursed in most European countries for the treatment of mCRC (15 out of 29 countries) and 
for GIST (14 out of 29 countries). In the majority of the European countries where it is reimbursed, 
regorafenib is free of charge. 
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4 HEALTH PROBLEM AND CURRENT USE OF THE TECHNOLOGY (CUR) 
4.1 Research questions 
Element ID Research question 
A0002 What is the disease or health condition in the scope of this assessment? 
A0003 What are the known risk factors for HCC? Are they likely to impact patients’ 
prognostic or treatment choice? 
A0004 What is the median survival of patients with HCC? What is the median survival 
of patients targeted in the claimed MA? 
A0005 What are the symptoms and the burden of HCC for the patient, in the targeted 
population? 
A0006 What is the burden of HCC for society in terms of prevalence, incidence, 
mortality and costs, in the defined population? 
A0024 How is HCC currently diagnosed according to published guidelines and in 
practice? 
A0025 How is HCC currently managed according to published guidelines and in practice? 
A0007 What is the target population in this assessment? 
A0023 How many people belong to the target population? 
A0011 How much are the technologies utilised? 
 
4.2 Results 
Overview of the disease or health condition 
A0002 – What is the disease or health condition in the scope of this assessment?  
A0003 – What are the known risk factors for HCC? Are they likely to impact patients’ 
prognostic or treatment choice? 
The health condition in the scope of this assessment is advanced HCC, specifically, adult patients 
who have been previously treated with sorafenib. 
 
Liver cancer is the sixth most common cancer (749,000 new cases, about 7% of all cancers) and 
represents the third-leading cause of cancer-related death (692,000 cases) [7]. HCC is the most 
common liver cancer (about 90% of the cases). The pattern of HCC occurrence has a clear geo-
graphical distribution, with the highest incidence rates in Eastern and South-eastern Asia and in 
sub-Saharan Black Africans [8], where around 85% of cases occur. HCC has a strong male pre-
ponderance with a male to female ratio estimated to be 2.4:1 [9]. 
 
HCC usually occurs in the setting of liver cirrhosis, which represents the largest single risk factor 
present in about 80–90% of all HCC cases [10]. Cirrhosis may be caused by chronic infections with 
hepatitis B virus (HBV) or hepatitis C virus (HCV), chronic alcohol consumption, non-alcoholic ste-
atohepatitis, or diabetes [11] There are many other risk factors but with lower importance, such as 
haemochromatosis, aflatoxin B1, tyrosinaemia, galactosaemia, fructosaemia, alpha 1 anti-trypsin 
deficiency, genetic predisposition, anabolising hormones, oestrogen contraceptives, obesity, and 
hypothyroidism. 
 
Based on a non-interventional surveillance study in 479 patients (from 39 countries) with unresec-
table HCC, the aetiology of the underlying liver disease in Europe based on 143 patients was alco-
hol use in 42%, infection with HCV in 33%, and HBV in 17% [12]. 
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All aetiologic forms of cirrhosis may be complicated by tumour formation, but the risk is higher in 
patients with hepatitis infection. Overall, one-third of cirrhotic patients will develop HCC during their 
lifetime. 
 
Several studies have identified HBV-related factors as key predictors of HCC development in pa-
tients with chronic hepatitis B infection, such as HBV e antigen (HBeAg) seropositivity, high viral 
load and genotype C [13]. Identification of mutations in germline DNA that define patients at high 
risk of developing cancer has become a challenge in HCC; some new findings, such as involvement 
of single nucleotide polymorphisms or an epidermal growth factor gene polymorphism, need to be 
further studied and validated. 
 
A0004 – What is the median survival of patients with HCC? What is the median survival of 
patients targeted in the claimed MA? 
Advanced HCC is generally associated with poor prognosis. The median survival time in patients 
diagnosed with unresectable disease is, depending on stage, estimated to be about 6–20 months, 
and the 5-year survival rate less than 5% [14] ). The median survival of the population scoped in 
this report (second line of advanced HCC) is estimated to be about 8 months[15] [16] [17]. 
 
In a 2009 systematic review of 72 studies, considering patients with cirrhosis and HCC (68 studies 
with advanced tumours), the most common predictors of mortality in HCC were: portal vein throm-
bosis (22/72 studies), tumour size (20/72 studies), alpha-fetoprotein (AFP; 20/72 studies), Child–
Pugh class (18/72 studies) and bilirubin (15/72 studies) [18]. 
 
 
Effects of the disease or health condition 
A0005 – What are the symptoms and the burden of HCC for the patient, in the targeted 
population? 
HCC in the early stages may be asymptomatic, but as the disease progresses, patients may expe-
rience one or more clinical symptoms: anorexia/cachexia, ascites, asthenia, early satiety, fatigue, 
fever, hepatic bruits, hepatic encephalopathy, jaundice, nausea and vomiting, nodular liver, palpa-
ble liver mass, peripheral oedema, pruritus, right upper quadrant pain, splenomegaly, variceal 
bleeding, weight loss. 
 
The stage of the disease together with the occurrence of severe symptoms adds up to a worsened 
prognosis, which in turn impacts functional status and patient quality of life [19] [20] [21] [22]. Alt-
hough diagnosis at earlier stages of the disease allows for treatment options with a possibility of 
cure, even with local therapies of resection and ablation, 5-year survival can be as low as 50% [7] 
[23]. Further, 63.8% of HCC patients undergoing surgical resection and >70% of those undergoing 
ablation techniques will have recurrence of HCC tumours 5 years after local therapy [24]. For pa-
tients with advanced disease, a cure is generally not expected. They usually experience a variety 
of symptoms, greatly impacting daily living activities, including pain, deterioration of quality of life 
and decline of fitness for work. HCC patients scored the lowest in terms of health-related quality of 
life (HRQoL) on a visual analogue scale (VAS) compared with patients classified with other chronic 
liver diseases (i.e., chronic hepatitis or cirrhosis) [25]. Overall, the burden of disease for the patient 
is considered to be very high. 
 
A0006 – What is the burden of HCC for society in terms of prevalence, incidence, mortality 
and costs, in the defined population? 
HCC is the third-leading cause of cancer-related death, and the global incidence is rising, with ap-
proximately 700,000 cases diagnosed worldwide in 2012 [26] [27]. In the US, the incidence of HCC 
is approximately 6.8/2.2 (male/female) 9.18 per 100,000 people, in Southern Europe 9.8/3.2 
(male/female), in Western Europe 7.2/2.1 (male/female), and in Northern Europe 3.8/1.6 (male/fe-
male) per 100,000 people [28]. The incidence of HCC has risen in the last 10 years and it varies 
geographically largely due to variations in the incidence of HBV and HCV infection, with the majority 
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of cases (>80%) occurring in sub-Saharan Africa and eastern Asia. One country alone, China, ac-
counts for 40–50% of worldwide cases. 
 
Since HCC can be considered as a complication of frequent clinical conditions, such as chronic 
infections with HBV or HCV, chronic alcohol consumption, non-alcoholic steatohepatitis, or diabe-
tes, the consequences for society are strong, namely regarding the consumption of resources (hos-
pitalisations, need of advanced techniques for diagnosis and treatment). 
 
Overall, the burden of the disease for society in the scoped population can be considered as mod-
erate given the prevalence of patients in the second line of advanced HCC. As the development of 
direct-acting antiviral agents will probably have a positive impact on HCV incidence and may, over 
time, also impact HCC incidence. Therefore, the burden of HCC for society in Europe may decrease 
in the coming years. 
 
 
Current clinical management of the disease or health condition 
A0024 – How is HCC currently diagnosed according to published guidelines and in practice? 
A0025 – How is HCC currently managed according to published guidelines and in practice? 
 
This section is supported by clinical practice guidelines from various scientific organisations: EASL-
EORTC [11], ESMO-ESDO [7], NCCN [29], and AASLD [30] see Table A5 for details. 
 
Pathological diagnosis of HCC requires a biopsy of the tumour. In some cases, notably for cirrhotic 
patients, a formal pathological proof is not necessary and the diagnosis can be based on non-
invasive imaging criteria for lesion characterisation obtained by 4-phase multidetector computed 
tomography (CT) scan or dynamic contrast-enhanced magnetic resonance imaging (MRI). Addi-
tional immunohistochemical assessment may be helpful such as: staging of glypican-3 (GPC3), 
neovascularisation (CD34) or potential progenitor cell origin (Keratin 19, EpCAM). 
 
As HCC generally occurs because of cirrhosis, the management of this disease should be global, 
taking into account the general state of patients and the underlying disease. 
 
When diagnosed at an early stage, patients may be eligible for curative treatments mainly repre-
sented by surgical resection, radiofrequency ablation or liver transplantation. At an intermediate 
(multinodular) stage or for patients who progress to an intermediate stage, transcatheter arterial 
chemoembolisation (TACE) is generally the preferred option. For patients diagnosed with an ad-
vanced tumour or for those who progress to an advanced disease, therapeutic management de-
pends on the general state. Sorafenib is the standard systemic therapy indicated for patients with 
a well-preserved liver function (Child-Pugh A) and a good performance status (ECOG ≤2) with the 
objective to increase survival but not to cure the disease. There is little evidence to support the use 
of sorafenib in Child-Pugh B patients. Although it can be recommended by some scientific societies, 
with a low strength of evidence sorafenib faces some reimbursement restriction in Child-Pugh B 
patients1. Until the regorafenib extension of indication, no drug was approved or recommended for 
patients who had been previously treated with sorafenib. Only BSC or inclusion in clinical trials were 
recommended. For patients with end-stage disease (Child-Pugh C or ECOG >1), only BSC with 
symptomatic treatment are advocated. 
 
Overall, there is a high unmet need in the population scoped in this report. 
 
Figure 4.1 shows the algorithm included in the guideline of the Barcelona Clinic Liver Cancer 
(BCLC), which is in agreement with the European Association for the Study of the Liver (EASL) and 
the European Organisation for Research and Treatment of Cancer (EORTC). 
 
                                            
1 Restricted to Child-Pugh A in France and Italy. Restricted to Child-Pugh A, adequate renal and hematopoietic functions in 
Croatia. 
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The BCLC system is widely used and encompasses all HCC patients. It divides HCC patients in 5 
stages (0, A, B, C and D) according to pre-established prognostic variables, and allocates therapies 
according to treatment-related status. Thus, it provides information on both prognostic prediction 
and treatment allocation. Prognosis prediction is defined by variables related to tumour status (size, 
number, vascular invasion, N1, M1), liver function (Child–Pugh status) and health status (ECOG). 
Treatment allocation incorporates treatment-dependent variables, which have been shown to influ-
ence therapeutic outcome, such as bilirubin, portal hypertension or presence of symptoms – ECOG 
[12]. 
 
 
Figure 4.1: Overview of the current clinical pathway for different stages of HCC based on 
BCLC staging 
 
 
Abbreviations: BCLC=Barcelona Clinic Liver Cancer; HCC=hepatocellular carcinoma; PS=performance status. 
Source: BCLC [31]. 
 
For patients requiring second-line therapy, EASL-EORTC [24] and ESMO-ESDO [25] recom-
mended BSC or a clinical trial, while LAASL [27] did not make any recommendation. With recent 
approval of regorafenib in the US, the NCCN Guideline on Hepatobiliary Cancers was updated and 
regorafenib is included as the only recommended treatment for progression on or after sorafenib 
treatment (in patients with Child-Pugh Class A only) [(26]. 
 
An overview of European guidelines for HCC treatment is given in Table A5 in Appendix 1. 
 
Target population 
A0007 – What is the target population in this assessment? 
The target population is that detailed in the summary of product characteristics (SmPC) for regoraf-
enib – clinical particulars: "Stivarga is indicated as monotherapy for the treatment of adult patients 
with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib" (EMA, July 
4th, 2017).  
 
A0023 – How many people belong to the target population? 
No relevant epidemiological studies were identified in the scientific literature to quantify the number 
of individuals who belong to the target population. According to the RESORCE study’s inclusion 
and exclusion criteria (cf. section 5), the target population is represented by patients with advanced 
HCC, who progressed on sorafenib treatment and are eligible to a second- or third-line systemic 
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treatment: tolerated sorafenib, well-preserved liver function (Child-Pugh A) and a good general state 
(ECOG 0-1): 
 The incidence of HCC in Southern Europe is approximately 9.8/3.2 (male/female), in Western 
Europe 7.2/2.1 (male/female), and in Northern Europe 3.8/1.6 (male/female) per 100,000 
people [28]. 
 Two subgroups of this target population can be identified: 
o patients with BCLC stage B at diagnosis (approximately 11%) treated by sorafenib 
after progression on or after TACE [32] 
o patients with BCLC stage C at diagnosis (approximately 51%) treated by sorafenib 
[32]. 
Given the poor prognosis of these fragile patients and because of the restricted eligibility criteria for 
this drug, only a small proportion of patients with advanced HCC can benefit from treatment with 
regorafenib in clinical practice. 
 
A0011 – How much are the technologies utilised? 
There is no published data from Europe regarding utilisation of regorafenib in this extension of 
indication as this technology has not yet been used for HCC in daily practice in most European 
countries. 
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5 CLINICAL EFFECTIVENESS (EFF) 
5.1 Research questions 
Element ID Research question 
D0001 What is the expected beneficial effect of regorafenib on mortality? 
D0005 How does regorafenib affect symptoms and findings (severity, frequency) of the 
disease or health condition? 
D0006 How does regorafenib affect progression (or recurrence) of the disease or health 
condition? 
D0012 What is the effect of regorafenib on generic health-related quality of life (EQ-
5D)? 
D0013 What is the effect of regorafenib on disease-specific quality of life (FACT-hep)? 
 
5.2 Results 
Included study 
The relative effectiveness assessment of regorafenib in this indication is based on the RESORCE 
study (NCT01774344) sponsored by the MAH [33]. This pivotal study is a randomised, double-blind, 
placebo-controlled phase III trial comparing regorafenib plus BSC with placebo plus BSC in patients 
with HCC who had progressed while on sorafenib. 
Inclusion and non-inclusion criteria 
Adult patients (≥18 years of age) with this type of cancer were enrolled from 152 centres in 21 
countries. The main inclusion and non-inclusion criteria are summarised in Table 5.1. 
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Table 5.1: Main inclusion and non-inclusion criteria of the RESORCE trial 
Main inclusion criteria Main non-inclusion criteria 
 Histological or cytological confirmation of hepatocellular carcinoma (HCC) or non-
invasive diagnosis of HCC as per American Association for the Study of Liver Dis-
eases (AASLD) criteria in subjects with a confirmed diagnosis of cirrhosis. 
 Barcelona Clinic Liver Cancer (BCLC) stage Category B or C that could not benefit 
from treatments of established efficacy with higher priority such as resection, local 
ablation, chemoembolisation, or systemic sorafenib. 
 Failure on prior treatment with sorafenib (defined as documented radiological pro-
gression according to the radiology charter). Randomisation needed to be performed 
within 10 weeks after the last treatment with sorafenib. 
 Tolerability to prior treatment with sorafenib defined as not less than 20 days at a 
minimum daily dose of 400 mg once daily within the last 28 days prior to withdrawal. 
 Liver function status Child-Pugh Class A. 
 Local or loco-regional therapy of intrahepatic tumour lesions (e.g., surgery, radiation 
therapy, hepatic arterial embolisation, chemoembolisation, radiofrequency ablation, 
percutaneous ethanol injection, or cryoablation) must have been completed 
≥4 weeks before first dose of study medication. Note: subjects who received sole 
intrahepatic intra-arterial chemotherapy, without lipiodol or embolising agents, were 
not eligible. 
 ECOG Performance Status of 0 or 1. 
 Adequate bone marrow, liver and renal function  
 At least one unidimensional measurable lesion by computed tomography (CT) scan 
or magnetic resonance imaging (MRI) according to Response Evaluation Criteria in 
Solid Tumors (RECIST) 1.1, and mRECIST for HCC. Tumour lesions situated in a 
previously irradiated area, or in an area subjected to other loco-regional therapy, may 
have been considered measurable if there had been demonstrated progression in the 
lesion. 
 Life expectancy of at least 3 months. 
 Prior liver transplantation or candidates for liver transplantation. 
 Prior treatment with regorafenib. Subjects permanently withdrawn from study par-
ticipation were not allowed to re-enter the study. 
 Prior and/or concomitant treatment within a clinical study other than with sorafenib 
during or within 4 weeks of randomisation. 
 Sorafenib treatment within 2 weeks of randomisation. 
 Subjects with large oesophageal varices at risk of bleeding that were not being 
treated with conventional medical intervention: beta blockers or endoscopic treat-
ment. The assessment of oesophageal varices (for subjects in whom conventional 
medical intervention for known oesophageal varices was already in place), was to 
be performed by endoscopy as per local standard of care. 
 Prior systemic treatment for HCC, except sorafenib. 
 Permanent discontinuation of prior sorafenib therapy due to sorafenib related tox-
icity. 
 Permanent discontinuation of prior sorafenib therapy due to any cause more than 
10 weeks prior to randomisation. 
 Past or concurrent history of neoplasm other than HCC, except for in situ carcinoma 
of the cervix, uteri, and/or non-melanoma skin cancer and superficial bladder tu-
mours (Ta [Non-invasive tumour], Carcinoma in situ [Tis] and T1 [Tumour invades 
lamina propria]).11 Any cancer curatively treated >3 years prior to study entry was 
permitted. 
 Known history or symptomatic metastatic brain or meningeal tumours (head CT or 
MRI at screening to confirm the absence of central nervous system [CNS] disease 
if the subject had symptoms suggestive or consistent with CNS disease). 
 Major surgical procedure or significant traumatic injury within 28 days before ran-
domisation. 
 Congestive heart failure New York Heart Association (NYHA) ≥ Class 2. 
 Unstable angina (angina symptoms at rest, new-onset angina i.e., within the last 
3 months) or myocardial infarction (MI) within the past 6 months before randomisa-
tion. 
 Cardiac arrhythmias requiring anti-arrhythmic therapy (beta blockers or digoxin 
were permitted). 
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Abbreviations: AASLD=American Association for the Study of Liver Diseases; BCLC=Barcelona Clinic Liver Cancer; CNS=central nervous system; CT=computed tomography; CTCAE=common 
terminology criteria for adverse events; HCC=hepatocellular carcinoma; HIV=human immunodeficiency virus; MI=myocardial infarction; mRECIST=modified response evaluation criteria in solid tumors; 
MRI=magnetic resonance imaging; NCI=National Cancer Institute; NYHA=New York Heart Association; RECIST=response evaluation criteria in solid tumors. 
Source:  clinical study report 
 
 Uncontrolled hypertension. 
 Subjects with phaeochromocytoma. 
 Uncontrolled ascites (defined as not easily controlled with diuretic or paracentesis 
treatment). 
 Pleural effusion or ascites that caused respiratory compromise (Grade ≥2 dysp-
noea). 
 Persistent proteinuria of NCI-CTCAE Grade 3 or higher. 
 Ongoing infection > Grade 2. Hepatitis B was allowed if no active replication was 
present. Hepatitis C was allowed if no antiviral treatment was required. 
 Clinically significant bleeding Grade 3 or higher within 30 days before randomisa-
tion. 
 Arterial or venous thrombotic or embolic events such as cerebrovascular accident 
(including transient ischaemic attacks), deep vein thrombosis or pulmonary embo-
lism within 6 months before the start of study medication. 
 Unresolved toxicity higher than Grade 1 (excluding alopecia or anaemia) attributed 
to any prior therapy/procedure. 
 Known history of human immunodeficiency virus (HIV) infection. 
 Seizure disorder requiring medication. 
 History of organ allograft. 
 Non-healing wound, ulcer, or bone fracture. 
 Renal failure requiring haemo- or peritoneal dialysis. 
 Interstitial lung disease with ongoing signs and symptoms at the time of screening. 
 Any malabsorption condition. 
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Treatments and randomisation 
An interactive voice response system (IVRS) was used to randomly allocate (in a double-blind fash-
ion) in a 2:1 ratio to either: 
‐ regorafenib 160 mg (4 x 40 mg tablets) orally (by mouth) every day for 3 weeks followed 
by 1 week off treatment (schedule 3/1) plus BSC or  
‐ matching placebo tablets with a 3/1 schedule plus BSC. 
 
BSC included any concomitant medications or treatments such as: antibiotics, analgesics, radiation 
therapy for pain control (limited to bone metastases), corticosteroids, transfusions, psychotherapy, 
growth factors, palliative surgery, or any other symptomatic therapy necessary to provide BSC, 
except other investigational antitumour agents or antineoplastic chemo/hormonal/immunotherapy. 
 
Subjects could continue on treatment until one of the following main criteria was observed: 
- Progressive disease (PD) as defined by mRECIST 
- Clinical progression (e.g., defined as worsening of the ECOG performance status (PS) score 
≥3 or symptomatic deterioration including increase in liver function tests) 
- Death due to any cause 
- Unacceptable toxicity 
- Subject withdraws consent 
- Treating physician determines discontinuation of treatment is in the subject’s best interest 
- Substantial non-compliance with the protocol 
- Or until any other criterion for stopping therapy was met. 
 
Up to two regorafenib dose reductions due to toxicity were allowed (from 160 mg to 120 mg to 
80 mg). The dose could be re-escalated to a maximum of 160 mg at the investigator’s discretion 
once toxicities were resolved. 
 
Patients were followed up for tumour assessments every 6 weeks for the first eight cycles and every 
12 weeks thereafter during treatment. 
 
Subjects were stratified according to: 
‐ Geographical region (Asia versus the rest of the world [ROW]); the proportion of patients 
recruited from Asia was limited to 40% 
‐ Eastern Cooperative Oncology Group (ECOG) performance status (0 versus 1) 
‐ Alpha-fetoprotein (AFP) levels (<400 ng/mL versus ≥400 ng/mL) 
‐ Extrahepatic disease (presence versus absence) 
‐ Macrovascular invasion (presence versus absence). 
 
Objective and endpoints 
The primary objective of the RESORCE trial was to demonstrate the superiority of regorafenib plus 
BSC versus placebo plus BSC in terms of OS. This primary endpoint is defined as the time from 
the date of randomisation to death due to any cause. 
 
Other endpoints included:  
- Progression-free survival (PFS) defined as the time (in days) from date of randomisation to date 
of disease progression (radiological or clinical) or death due to any cause (if death occurred 
before progression was documented). PFS was assessed by the investigators. 
- Objective response rate (ORR) defined as the rate of subjects with complete response (CR) or 
partial response (PR) over all randomised subjects. Subjects prematurely discontinuing without 
an assessment were to be considered non-responders for the analysis. 
- HRQoL assessed using the functional assessment of cancer therapy questionnaire for patients 
with hepatobiliary cancer (FACT-Hep) and the EuroQoL five dimensions questionnaire (EQ-5D) 
index and VAS scores. 
- Duration of response (DOR) was defined as the time from the first documented objective re-
sponse of PR or CR, whichever was noted earlier, to disease progression or death (if death 
occurred before progression was documented). 
- Biomarker evaluation. 
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As a reminder, HTA bodies involved with this REA stated that: 
- The critical efficacy outcomes were: OS and HRQoL. 
- The important efficacy outcome was: PFS. 
- The critical or important safety outcomes were: any AEs, SAEs, grade ≥3 AEs, discontinuation 
due to AEs and AEs of special interest (Risk Management Plan). 
 
 
Statistical analysis 
 
Sample size 
The sample size was based on the primary efficacy endpoint: OS. The targeted improvement was 
a 43% increase in median OS compared with placebo (i.e., assuming a median OS under placebo 
of 8 months, the median under regorafenib was expected to be at least 11.4 months). The associ-
ated hazard ratio (HR) of regorafenib over placebo was 0.7. Approximately 370 events were re-
quired assuming a one-sided alpha of 0.025, a targeted improvement in median survival of 43%, a 
power of 90%, and a randomisation ratio of 2:1 between regorafenib and placebo. Approximately 
560 patients should have been randomised to conduct the study in a reasonable time frame. 
The assumption of 8 months OS in the placebo plus BSC group was based on four previously 
performed randomised trials that evaluated patients undergoing a second-line treatment [15] [16] 
[17] [29]. 
Analysis sets 
The primary efficacy analysis was performed using the full analysis set (FAS), which was defined 
as all randomised patients (intention to treat analysis). The population for the safety analysis (SAF 
population) comprised all randomised patients who received at least one dose of study medication 
(regorafenib or placebo). 
 
Endpoints analysis 
o Overall survival 
For each treatment arm, the following parameters and analyses were provided: Kaplan-Meier prod-
uct-limit estimates of the OS distribution functions and the OS time (median and its 95% confidence 
interval [CI]). The HR of regorafenib over placebo and its 95% CI were generated from the Cox 
model. The analysis was performed according to treatment groups as randomised, with stratification 
as recorded in the IVRS data. A Kaplan-Meier plot displaying the OS curves of the two treatment 
groups was provided. 
A one-sided overall alpha of 0.025 was used for the efficacy analysis of OS. The analysis of OS 
was planned when approximately 370 deaths were observed (information fraction=1.0). 
 
o Other endpoints 
PFS was analysed with a one-sided significance level of alpha=0.025. ORR and DOR were ana-
lysed descriptively only. For the secondary endpoints, analyses were displayed for both RECIST 
version 1.1 and mRECIST. 
HRQoL was assessed during the trial using a generic scale (EQ-5D index and VAS) and a disease-
specific scale (FACT-Hep). The FACT-Hep and EQ-5D were both self-administrated by the subject 
at baseline, at every cycle, and at the end-of-study visit before seeing the physician. 
 
For the EQ-5D, higher scores represented better health status. A change of at least 0.1 points on 
the EQ-5D index was considered to be a minimum important difference (MID) (using ECOG PS as 
the anchor). A change of at least 7 points on the VAS was considered as a MID [34]. 
 
The FACT-Hep consisted of the 27-item FACT-G, a core questionnaire designed to measure gen-
eral aspects of HRQoL in subjects with any form of cancer, and the newly validated 18-item Hepato-
biliary Cancer Subscale (HCS), designed to measure specific concerns or problems related to QoL 
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in subjects with hepatobiliary cancers (FACT-Hep = FACT-G + HCS). It contained five domains: 
Physical Well-Being, Social Well-Being, Emotional Well-Being, Functional Well-Being and Hepato-
biliary Cancer Subscale. A change of at least 8–9 points on the FACT-hep score was considered 
as a MID [35]. 
 
PRO data as measured by FACT-Hep and EQ-5D were analysed to assess differences in HRQoL 
and health utility values between treatment arms based on time adjusted AUC using all available 
data. Statistical tests were performed using a 2-sided type I error of 5%. 
In case of missing responses for one or more items, subscale scores were permitted to be prorated: 
- For FACT-Hep, this was done by multiplying the sum of the subscale by the number of items in 
the scale, then dividing the number of items actually answered. Prorating of scores was consid-
ered acceptable as long as more than 50% of the items were answered (assuming that the score 
of missing items was similar to those of non-missing items). If less than or equal to 50% of the 
items were answered for any domain, then the score of that domain was set to missing. The total 
score was then calculated as the sum of the unweighted subscale scores. Moreover, the FACT-
Hep total score was set to missing if the related overall item response rate was less than or equal 
to 80%. 
- For EQ-5D, if there was a missing or ambiguous answer (i.e., marking of more than one answer) 
on the five dimension questions, then the index score was marked as missing. 
Neither hierarchy nor other adjustment for multiplicity analysis was planned to control for type I 
error. 
 
Results 
 
The main results presented in this report are based on the primary analysis (with a cut-off date in 
February 2016; database lock in August 2016). Data reported in this REA are based on the CSR 
provided by the MAH. Authors were notified that between database lock and May 2017 some indi-
vidual data were rectified leading to minor variations on efficacy and safety outcomes and explaining 
slight differences between this report and the SmPC. 
 
Overall, 573 patients were randomised in the RESORCE trial: 379 in the regorafenib plus BSC 
group and 194 in the placebo plus BSC group. Demographic and baseline disease characteristics 
were balanced across both treatment arms (see Table 5.2). 
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Table 5.2: Demographic and baseline characteristics 
 Placebo 
N=194 (100%) 
Regorafenib 
N=379 (100%) 
Sex 
Male 
Female 
 
171 (88.1%) 
23 (11.9%) 
 
333 (87.9%) 
46 (12.1%) 
Calculated age at enrolment (years) 
N 
Median (range)  
Age group 
<65 years 
≥65 years 
 
194 
62.0 (23-83) 
 
116 (59.8%) 
78 (40.2%) 
 
379 
64.0 (19-85) 
 
199 (52.5%) 
180 (47.5%) 
Geographic region (from stratification) 
Asia 
Rest of the world 
 
73 (37.6%) 
121 (62.4%) 
 
143 (37.7%) 
236 (62.3%) 
Baseline value of ECOG Performance Status  
0 
1 
 
130 (67%) 
64 (33%) 
 
247 (65%) 
132 (35%) 
Weeks since initial diagnosis to start of study 
treatment 
N 
Median (range) 
 
 
173 
87.9 (10.9-531.1) 
 
 
335 
92.7 (8.7-1129.0) 
Weeks since the most recent progression/re-
lapse to start of study treatment 
N 
Median  
 
 
193 
5.1 (0.6-32.4) 
 
 
374 
5.4 (0.3-33.9) 
Aetiology of HCC 
Alcohol use 
Hepatitis B 
Hepatitis C 
Genetic/metabolic  
Non-alcoholic steatohepatitis (NASH) 
Unknown  
Other 
 
55 (28.4%) 
73 (37.6%) 
41 (21.1%) 
6 (3.1%) 
13 (6.7%) 
32 (16.5%) 
4 (2.1%) 
 
90 (23.8%) 
143 (37.7%) 
78 (20.6%) 
16 (4.2%) 
25 (6.6%) 
66 (17.4%) 
12 (3.2%) 
TNM stage at study entry 
Stage I 
Stage II 
Stage IIIA 
Stage IIIB 
Stage IIIC 
Stage IVA 
Stage IVB 
 
0 
12 (6.2%) 
16 (8.3%) 
18 (9.3%) 
0 
17 (8.8%) 
130 (67.0%) 
 
2 (0.5%) 
27 (7.1%) 
36 (9.5%) 
41 (10.8%) 
5 (1.3%) 
22 (5.8%) 
245 (64.6%) 
BCLC stage at study entry 
A (early stage) 
B (intermediate stage) 
C (advanced stage) 
 
0 
22 (11.3%) 
172 (88.7%) 
 
1 (0.3%) 
53 (14.0%) 
325 (85.8%) 
Alpha-fetoprotein (AFP) (ng/ml) 
<400 ng/mL 
≥400 ng/mL 
 
107 (55.2%) 
87 (44.9%) 
 
217 (57.3%) 
162 (42.7%) 
Macrovascular invasion 
Absence 
Presence 
 
140 (72.2%) 
54 (27.8%) 
 
269 (71.0%) 
110 (29.0%) 
Extrahepatic disease 
Absence 
Presence 
 
47 (24.2%) 
147 (75.8%) 
 
114 (30.1%) 
265 (69.9%) 
Child-Pugh Score 
Missing 
A 
B 
 
0 
188 (96.9%) 
6 (3.1%) 
 
1 (0.3%) 
373 (98.4%) 
5 (1.3%) 
Liver cirrhosis (medical history) 
No 
Yes 
 
50 (25.8%) 
144 (74.2%) 
 
94 (24.8%) 
285 (75.2%) 
Abbreviations: AFP=alpha-fetoprotein; BCLC=Barcelona Clinical Liver Cancer classification; ECOG=Eastern 
Cooperative Oncology Group; HCC=hepatocellular carcinoma; NASH=non-alcoholic steatohepatitis; TNM=classification of 
Malignant Tumours 
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Sources: clinical study report and MAH submission file. 
 
The numbers of patients with at least one concomitant medication are reported in Table 5.3. A trend 
to a higher rate of concomitant medications in the regorafenib group is observed. 
 
Table 5.3: Concomitant medication 
ATC class WHO-DD version (3q2005) 
Placebo 
N=194 
Regorafenib 
N=379 
Number of subjects (%) with at least 1 concomitant medication 
Alimentary tract and metabolism 
Anti-infectives for systemic use 
Antineoplasic and immunomodulating agents 
Antiparasitic products, insecticides and repellents 
Blood and blood forming organs 
Cardiovascular system 
Dermatologicals 
Genitourinary system and sex hormones 
Musculoskeletal system 
Nervous system 
Respiratory system 
Sensory organs 
Systemic hormonal preparations, excl. sex hormones and insulin  
Unclassifiable 
Various 
187 (96.4%) 
148 (76.3%) 
93 (47.9%) 
26 (13.4%) 
7 (3.6%) 
110 (56.7%) 
149 (76.8%) 
76 (39.2%) 
88 (45.4%) 
66 (34.0%) 
136 (70.1%) 
68 (35.1%) 
74 (38.1%) 
50 (25.8%) 
2 (1.0%) 
96 (49.5%) 
372 (98.2%) 
330 (87.1%) 
220 (58.0%) 
60 (15.8%) 
22 (5.8%) 
237 (62.5%) 
321 (84.7%) 
213 (56.2%) 
190 (50.1%) 
146 (38.5%) 
265 (69.9%) 
182 (48.0%) 
183 (48.3%) 
126 (33.2%) 
6 (2.1%) 
192 (50.7%) 
Abbreviations: ATC=anatomical therapeutic chemical; WHO-DD=World Health Organization Drug Dictionary. 
Sources: clinical study report and MAH submission file. 
 
Mortality 
D0001 – What is the expected beneficial effect of regorafenib on mortality? 
The median OS time was 10.6 months (95% CI 9.1, 12.1 months) in the regorafenib group com-
pared with 7.8 months (95% CI 6.3, 8.8 months) in the placebo group with an HR of 0.627 (95% CI 
0.500, 0.785), one sided p-value from the log rank test stratified =0.00002. The absolute gain was 
2.8 months in favour of regorafenib. 
 
Following the authors’ request, the MAH provided a bootstrap analysis to estimate the mean and 
95% CI of the difference of OS median times at the time of the primary analysis. At this time, the 
mean difference in terms of OS median times between the two arms was: 2.7 months (95% CI 0.8, 
5.0). 
 
A Kaplan-Meier analysis for OS for the FAS is presented in Figure 5.1. 
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Figure 5.1: Kaplan-Meier curves of OS (FAS population) 
 
 
Abbreviations: FAS=full analysis set; OS=overall survival. 
Sources: clinical study report and MAH submission file. 
 
Subgroup analysis suggested a consistent effect of regorafenib in almost every subgroup, expect 
females, absence of extrahepatic disease, HCC aetiology hepatitis C, Child-Pugh score A6, ECOG 
=1, age ≥65 years old, and alcohol use. However, considering the reduced size in these subgroups, 
these data are to be interpreted with caution (see Figure 5.2 and Table 5.4). 
 
 
Figure 5.2: Forest plot of subgroup analyses: OS  
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Abbreviations: AFP=alpha-fetoprotein; ECOG=Eastern Cooperative Oncology Group; HCC=hepatocellular carcinoma; 
OS=overall survival. 
Sources: clinical study report and MAH submission file. 
 
Table 5.4: Summary subgroup analyses of OS – inferential statistics  
 
Abbreviations: AFP=alpha-fetoprotein; ECOG=Eastern Cooperative Oncology Group; HCC= hepatocellular carcinoma; 
OS=overall survival; PS=performance score. 
Sources: clinical study report and MAH submission file. 
 
An updated analysis was performed by the MAH almost 1 year later (with a cut-off date of 23 Jan-
uary 2017). On this date, 4 of the 194 patients randomised into the placebo group had switched to 
regorafenib. Overall, this updated analysis was consistent with the primary analysis: HR=0.614 
(95% CI 0.501, 0.753), p=0.000001. The updated median OS was 10.7 months in the regorafenib 
group and 7.9 months in the placebo group. 
 
Morbidity 
D0005 – How does regorafenib affect symptoms and findings (severity, frequency) of the 
disease or health condition? 
D0006 – How does regorafenib affect progression (or recurrence) of the disease or health 
condition?  
PFS (by investigators) 
The median PFS time using mRECIST was 3.1 months (95% CI 2.8, 4.2) in the regorafenib group 
compared with 1.5 months (95% CI 1.4, 1.6) in the placebo group: HR=0.455 (95% CI 0.371, 0.558). 
The absolute gain was 1.6 months in favour of regorafenib (see Figure 5.3). 
 
Similar results were observed using RECIST 1.1: the median PFS time was 3.4 months (95% CI 
2.9, 4.2) in the regorafenib group compared with 1.5 months (95% CI 1.4, 1.5) in the placebo group: 
HR=0.427 (95% CI 0.348, 0.524). The absolute gain was 1.9 months in favour of regorafenib. 
 
A consistent effect on PFS was observed across the subgroup analysis (not detailed in this report). 
 
No PFS assessment was performed by an independent review committee. 
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Figure 5.3: Kaplan-Meier curves of PFS (FAS) (mRECIST) 
 
Abbreviations: FAS=full analysis set; mRECIST=modified response evaluation criteria in solid tumors; PFS=progression 
free survival. 
Sources: clinical study report and MAH submission file. 
 
 
Objective response rate (ORR) and duration of response (DOR) 
The ORR to treatment according to mRECIST was 10.6% in the regorafenib group compared with 
4.1% in the placebo group: difference =-6.61% (95% CI -10.84, -2.39). Most of the responses were 
partial; only two patients reach a CR in the regorafenib group. 
 
The ORR to treatment according to RECIST 1.1 was 6.6% in the regorafenib group compared with 
2.6% in the placebo group: difference =-4.15% (95% CI -7.55, -0.75). The responses were exclu-
sively partials. 
The median DOR according to mRECIST was 3.5 months (106 days) in the regorafenib group com-
pared with 2.7 months (81 days) in the placebo group. 
 
The median DOR according to RECIST 1.1 was 5.9 months (179 days) in the regorafenib group 
compared with 5.6 months (169 days) in the placebo group. 
 
Biomarker analysis 
An exploratory and retrospective analysis of biomarkers using a proteomic approach was performed 
and submitted by the MAH. This preliminary analysis was conducted on 499 patients representing 
87% of the total RESORCE population. The baseline plasma levels of 5 proteins (Ang1, Cystatin 
B, LAP-TGFβ, Lox1 and MIP1α) are potentially predictive for regorafenib treatment effect for OS 
(after adjustment for multiplicity) when analysed as continuous variables suggesting that an in-
crease in protein levels correlates with reduced benefit from regorafenib treatment. However, given 
the low level of evidence of this analysis (exploratory, retrospective), no formal conclusion can be 
drawn on a potential biomarker to predict regorafenib efficacy or safety. 
 
Post-study treatment 
During the follow-up, 130 patients (22.7%) were treated with another antineoplastic agent after pro-
gression of the disease: 76 patients in the regorafenib group and 54 patients in the placebo group. 
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Health-related quality of life 
D0012 – What is the effect of regorafenib on generic health-related quality of life (EQ-5D)? 
D0013 – What is the effect of regorafenib on disease-specific quality of life (FACT-hep)? 
At the end of the treatment (EOT), only half of the patients were evaluated: 
- Completion rate for the EQ-5D index at EOT: 56.7% (n=110/194) in the placebo group and 
47.0% (n=178/379) in the regorafenib group; 
- Completion rate for the EQ-5D VAS at EOT: 57.7% (n=112/194) in the placebo group and 
47.5% (n=180/379) in the regorafenib group; 
- Completion rate for the FACT-Hep scale at EOT: 57.2% (n=111/194) in the placebo group and 
47.0% (n=178/379) in the regorafenib group. 
 
The exploratory analysis of HRQoL suggested the absence of a clinically meaningful difference 
between regorafenib and placebo as measured by the EQ-5D and FACT-hep scales; see Figures 
5.4, 5.5, 5.6 and Table 5.5. However, no formal conclusion can be drawn on HRQoL given the non-
optimal level of evidence. 
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Figure 5.4: EQ-5D – means with 95% CI: EQ-5D index score (evaluable population) 
 
Abbreviations: CI=confidence interval; EQ-5D=EuroQoL five dimensions questionnaire. 
Sources: clinical study report and MAH submission file. 
 
Figure 5.5: EQ-5D – means with 95% CI: EQ-5D VAS (evaluable population) 
 
Abbreviations: CI=confidence interval; EQ-5D=EuroQoL five dimensions questionnaire; VAS=visual analogue scale. 
Sources: clinical study report and MAH submission file. 
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Figure 5.6: FACT-Hep – means with 95% CI: FACT-Hep Total (evaluable population) 
 
Abbreviations: CI=confidence interval; FACT-Hep=functional assessment of cancer therapy questionnaire for patients 
with hepatobiliary cancer. 
Sources: clinical study report and MAH submission file. 
 
Table 5.5: Patient reported outcomes (evaluable population) 
 Placebo 
N=194 
Regorafenib 
N=379 
difference p-value MID 
EQ-5D index 
 
EQ-5D VAS 
 
FACT-Hep total 
0.77  
(0.75, 0.79) 
73.45  
(71.84, 75.06) 
133.17  
(131.21, 135.12) 
0.76  
(0.75, 0.78) 
71.68  
(70.46, 72.90) 
129.31  
(127.84, 130.79) 
-0.01  
(-0.03, 0.02) 
-1.77  
(-3.58, 0.04) 
-3.85  
(-6.06, -1.65) 
0.47 
 
0.06 
 
0.0006 
0.1 
 
10 
 
8-9 
Results expressed as LSM time-adjusted AUC (95% CI) 
 
Abbreviations: AUC=area under the curve; CI=confidence interval; EQ-5D=EuroQoL five dimensions questionnaire; 
FACT-Hep=functional assessment of cancer therapy questionnaire for patients with hepatobiliary cancer; LSM=least 
squares method; MID=minimally important differences; VAS=visual analogue scale. 
Sources: clinical study report and MAH submission file.
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6 SAFETY (SAF) 
6.1 Research questions 
Element ID Research question 
C0008  How safe is regorafenib in relation to the comparator? 
D0011 What is the effect of regorafenib on patients’ body functions? 
C0005 What are the susceptible patient groups that are more likely to be harmed through 
the use of regorafenib? 
 
6.2 Results 
Included study 
The relative safety assessment of regorafenib in this indication was based on the randomised, dou-
ble-blind, placebo-controlled phase III RESORCE trial. Safety variables were analysed in all ran-
domised patients who received at least one dose of study medication: regorafenib or placebo. 
 
The overall median duration of treatment (including time interrupted) was considerably longer for 
the 374 patients in the regorafenib group (15.6 [0.1-0.128] weeks) than for the 193 patients in the 
placebo group (8.4 [0.7-0.119] weeks). 
 
Only half of the regorafenib group received the full protocol dose (160 mg/day) with no dose reduc-
tions: 184 of 374 (49.2%). 
 
 
Patient safety 
C0008 – How safe is regorafenib in relation to the comparators? 
D0011 – What is the effect of regorafenib on patients’ body functions? 
Treatment-emergent adverse events (TEAEs) 
Adverse events (AEs) occurred in all 374 of the 374 patients (100%) receiving regorafenib and in 
179 out of 193 patients (92.7%) receiving placebo. These AEs were related to study drug in 92.5% 
of patients in the regorafenib group and in 51.8% patients in the placebo group. 
 
The most frequently reported TEAEs (>25%) in the regorafenib group were hand–foot skin reaction 
(HFSR) (51.3% in the regorafenib and 6.7% in the placebo group), diarrhoea (41.2% in the regoraf-
enib and 15.0% in the placebo group), decreased appetite (30.7% in the regorafenib and 14.0% in 
the placebo group), hypertension (30.7% in the regorafenib and 6.2% in the placebo group), and 
fatigue (28.6% in the regorafenib and 24.4% in the placebo group); see Table 6.1. 
 
Table 6.1: Most frequently reported TEAEs (>25%) (SAF population) 
System organ class (SOC) preferred 
term 
TEAE Drug-related TEAE 
Regorafenib 
N=374(100%) 
Placebo 
N=193 (100%) 
Regorafenib 
N=374 (100%) 
Placebo 
N=193 (100%) 
Blood and lymphatic disorders   
Anemia 51 (13.6%) 21 (13.6%) 22 (5.9%) 2 (1.0%) 
Endocrine disorders   
Hypothyroidism 24 (6.4%) 0 - - 
Gastrointestinal disorders   - - 
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Abdominal distension 18 (4.8%) 10 (5.2%) - - 
Abdominal pain 79 (21.1%) 30 (15.5%) 26 (7.0%) 4 (2.1%) 
Abdominal pain upper 47 (12.6%) 17 (8.8%) - - 
Ascites 58 (15.5%) 31 (16.1%) - - 
Constipation 65 (17.4%) 21 (10.9%) 24 (6.4%) 3 (1.6%) 
Diarrhea 154 (41.2%) 29 (15.0%) 125 (33.4%) 18 (9.3%) 
Dry mouth 21 (5.6%) 9 (4.7%) - - 
Nausea 64 (17.1%) 26 (13.5%) 40 (10.7%) 13 (6.7%) 
Stomatitis 31 (8.3%) 4 (2.1%) 28 (7.5%) 3 (1.6%) 
Vomiting 47 (12.6%) 13 (6.7%) 27 (7.2%) 5 (2.6%) 
General disorders and administration site conditions   
Asthenia 56 (15.0%) 18 (9.3%) 42 (11.2%) 11 (5.7%) 
Edema peripheral 56 (15.0%) 26 (13.5%) - - 
Fatigue 107 (28.6%) 47 (24.4%) 79 (21.1%) 26 (13.5%) 
General physical health deterioration 44 (11.8%) 27 (14.0%) - - 
Malaise 22 (5.9%) 5 (2.6%) - - 
Pyrexia 74 (19.8%) 13 (6.7%) - - 
Investigations     
Alanine aminotransferase increased 54 (14.4%) 21 (10.9%) 28 (7.5%) 8 (4.1%) 
Aspartate aminotransferase increased 92 (24.6%) 38 (19.7%) 49 (13.1%) 15 (7.8%) 
Blood alkaline phosphatase increased 22 (5.9%) 8 (4.1%) - - 
Blood bilirubin increased 91 (24.3%) 31 (16.1%) 59 (15.8%) 5 (2.6%) 
GGT increased 22 (5.9%) 12 (6.2%) - - 
Lipase increased 27 (7.2%) 6 (3.1%) - - 
Platelet count decreased 34 (9.1%) 2 (1.0%) - - 
Weight decreased 50 (13.4%) 8 (4.1%) 26 (7.0%) 2 (1.0%) 
Metabolism and nutrition disorders     
Decreased appetite 115 (30.7%) 27 (14.0%) 88 (23.5%) 11 (5.7%) 
Hypoalbuminemia 52 (13.9%) 14 (7.3%) - - 
Hypokalemia 26 (7.0%) 5 (2.6%) - - 
Hyponatremia 21 (5.6%) 6 (3.1%) - - 
Hypophosphatemia 36 (9.6%) 4 (2.1%) 22 (5.9%) 2 (1.0%) 
Musculoskeletal and connective tis-
sue disorders 
    
Arthralgia 14 (3.7%) 11 (5.7%) - - 
Back pain 45 (12.0%) 17 (8.8%) - - 
Muscle spasms 38 (10.2%) 4 (2.1%) 23 (6.1%) 1 (0.5%) 
Musculoskeletal pain 17 (4.5%) 11 (5.7%) - - 
Pain in extremity 26 (7.0%) 6 (3.1%) - - 
Nervous system disorders     
Headache 24 (6.4%) 12 (6.2%) - - 
Psychiatric disorders     
Insomnia 24 (6.4%) 8 (4.1%) - - 
Renal and Urinary disorders     
Proteinuria 32 (8.6%) 2 (1.0%) 21 (5.6%) 2 (1.0%) 
Respiratory, thoracic and mediastinal disorders 
Cough 41 (11.0%) 13 (6.7%) - - 
Dysphonia 67 (17.9%) 3 (1.6%) 59 (15.8%) 2 (1.0%) 
Dyspnea 28 (7.5%) 15 (7.8%) - - 
Pleural effusion 15 (4.0%) 11 (5.7%) - - 
Skin and subcutaneous tissue disorders 
Alopecia 26 (7.0%) 5 (2.6%) 25 (6.7%) 5 (2.6%) 
Palmar-plantar erythrodysesthesia syn-
drome 
192 (51.3%) 13 (6.7%) 190 (50.8%) 11 (5.7%) 
Pruritus 19 (5.1%) 14 (7.3%) - - 
Rash 20 (5.3%) 14 (7.3%) - - 
Vascular disorders     
Hypertension 115 (30.7%) 12 (6.2%) 86 (23.0%) 9 (4.7%) 
Abbreviations: SAF=safety analysis population; SOC=system organ class; TEAE=treatment-emergent adverse event. 
Sources: clinical study report and MAH submission file. 
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Grade ≥3 AEs 
More Grade ≥3 AEs were observed in the regorafenib group (n=298, 79.7%; 51.9% drug-related) 
than in the placebo group (n=113, 58.5%; 17.6% drug-related); see Table 6.2. 
 
The five most frequent drug-related Grade 3 TEAEs in the regorafenib group were: hypertension 
(12.8%), HFSR (12.3%), blood bilirubin increased (5.1%), AST increased (4.5%) and hypophos-
phataemia (4.3%). The five most frequent drug-related Grade 4 TEAEs in the regorafenib group 
were: alanine transaminase (ALT) increased (0.5%), hypophosphataemia (0.5%), anaemia (0.3%), 
thrombocytopenia (0.3%) and acute coronary syndrome (0.3%). 
 
Table 6.2: Worst CTCAE grade of any AE and any drug-related AE 
Worst CTCAE grade Placebo N=193 Regorafenib N=374 
Any AE 
Grade 1 
Grade 2 
Grade 3 
Grade 4 
Grade 5 (death) 
Grade ≥3 
 
Any drug-related AE 
Grade 1 
Grade 2 
Grade 3 
Grade 4 
Grade 5 (death) 
Grade ≥3 
 
30 (15.5%) 
36 (18.7%) 
61 (31.6%) 
14 (7.3%) 
38 (19.7%) 
113 (58.5%) 
 
 
43 (22.3%) 
23 (11.9%) 
31 (16.1%) 
1 (0.5%) 
2 (1.0%) 
34 (17.6%) 
 
16 (4.3%) 
60 (16.0%) 
208 (55.6%) 
40 (10.7%) 
50 (13.4%) 
298 (79.7%) 
 
 
42 (11.2%) 
110 (29.4%) 
173 (46.3%) 
14 (3.7%) 
7 (1.9%) 
194 (51.9%) 
Abbreviation: AE=adverse event; CTCAE=common terminology criteria for adverse events. 
Sources: clinical study report and MAH submission file. 
 
Serious adverse events (SAEs) 
The overall incidence of SAEs was broadly similar in the two groups: 44.4% (n=166) in the regoraf-
enib group (10.4% drug-related) and 46.6% (n=90) in the placebo group (2.6% drug-related). Most 
of the SAEs observed in the regorafenib group were related to the following SOCs: general disor-
ders and administration site conditions (49 events, 13.1%), gastrointestinal disorders (32 events, 
8.6%), and hepatobiliary disorders (22 events, 5.9%). 
 
Grade 5 AEs (deaths) 
In total, at the time of the database cut-off, there were 9 TEAEs with a fatal outcome (Grade 5) 
within 30 days of last study drug that were reported as treatment-related in the clinical database: 7 
in the regorafenib group and 2 in the placebo group. Causes of TEAEs with a fatal outcome in the 
regorafenib group were: duodenal perforation, meningorrhagia, shock haemorrhagic, hepatic en-
cephalopathy, myocardial infarction, general physical health deterioration, and one unexplained 
death. 
 
Discontinuation and dose modification due to adverse events 
Dose modification (treatment interruption or dose reduction) because of an AE was required in 
68.2% of patients receiving regorafenib compared with 31.1% of patients receiving placebo. AEs 
leading to permanent discontinuation of the drug were also more frequently recorded in the regoraf-
enib group (24.9% versus 19.2%); see Table 6.3. 
 
TEAEs leading to discontinuation of study drug in at least 2% of subjects in the regorafenib group 
were: general physical health deterioration (3.7%), AST increased (2.4%), and blood bilirubin in-
creased (2.1%). 
PTJA02 - Regorafenib indicated as monotherapy for the treatment of adult patinets with hepatocellular carcinoma who 
have been previously treated with Sorafenib 
Version 1.2, October 2017  EUnetHTA Joint Action 3 WP4 46 
 
Table 6.3: Adverse events leading to dose modification or discontinuation of the drug (SAF 
population) 
 Placebo N=193 Regorafenib N=374 
Any AE 
Leading to a dose modification 
Leading to permanent discontinuation of study drug 
  
Any drug-related AE 
Leading to a dose modification 
Leading to permanent discontinuation of study drug 
 
60 (31.1%) 
37 (19.2%) 
 
 
20 (10.4%) 
7 (3.6%) 
 
255 (68.2%) 
93 (24.9%) 
 
 
202 (54.0%) 
39 (10.4%) 
Abbreviation: AE=adverse event; SAF=safety analysis population. 
Sources: clinical study report and MAH submission file. 
 
Adverse events of special interest (RMP) 
The Pharmacovigilance Risk Assessment Committee (PRAC) and the CHMP endorsed the risk 
management plan (RMP) with the ongoing safety concerns detailed in Table 6.4. 
 
Table 6.4: Risk management plan 
Important identified risks 
Severe drug-induced liver injury (DILI) 
Cardiac ischaemic events 
Hypertension and hypertensive crisis 
Haemorrhage 
Hand–foot skin reaction (HFSR) 
Posterior reversible encephalopathy syndrome (PRES) 
Gastrointestinal perforation and fistulae 
Stevens-Johnson syndrome (SJS)/Toxic epidermal necrolysis (TEN) 
Important potential risks 
Wound healing complications 
Interstitial lung disease (ILD) 
Atrial fibrillation 
Reproductive and developmental toxicity 
Renal failure 
Phototoxicity  
Thrombotic microangiopathies (TMA) 
Missing information 
Safety in severe hepatic impairment 
Safety in children 
Safety in patients with a cardiac history 
Safety in severe renal impairment  
Interaction with antibiotics 
Interaction with BCRP substrates 
Activity in KRAS mutated tumours or other biomarker defined tumour sub-
types 
Long-term safety in GIST patients 
Abbreviations: BRCP=breast cancer resistance protein; DILI=drug-induced liver injury; EMA=European Medicines 
Agency; HFSR=hand–foot skin reaction; ILD=interstitial lung disease; PRES=posterior reversible 
encephalopathy syndrome; SJS=Stevens-Johnson syndrome; TEN=toxic epidermal necrolysis; 
TMA=thrombotic microangiopathies. 
Source: EMA. 
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C0005 – What are the susceptible patient groups that are more likely to be harmed through 
the use of regorafenib? 
Differences in terms of safety profile were observed across races groups. Table 6.5 details the most 
common TEAEs (incidence of >10% overall in the regorafenib group) by race: White, Asian, or not 
reported. Incidences of HFSR in the regorafenib group were 66.5% for Asian patients and 42.2% 
for White patients. Other AEs reported more frequently in Asian patients in the regorafenib group 
included: ALT increased, AST increased, and hypoalbuminaemia. AEs reported more frequently in 
White subjects included: fatigue and hypothyroidism. 
No other subgroups were identified that are more likely to be harmed. 
Table 6.5: Most common TEAEs by race (>10% overall in regorafenib treatment group) 
(SAF) 
 
Abbreviations:ALT= alanine transaminase, AST= aspartate transaminase; MedDRA= Medical Dictionary for Regulatory 
Activities 
Sources: clinical study report and MAH submission file. 
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7 POTENTIAL ETHICAL, ORGANISATIONAL, PATIENT AND SOCIAL, AND 
LEGAL ASPECTS (ETH, ORG, SOC, LEG) 
Not applicable. 
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8 PATIENT INVOLVEMENT  
WP4 emphasises the importance of including the patient’s perspective in producing Joint 
Assessments. For this specific Joint Assessment, several patient organisations have been 
contacted to assist in identifying patients who may be interested in participating in the Joint 
Assessment. However, no response from patients has been received. 
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9 DISCUSSION 
On 04 July 2017, the CHMP adopted a positive opinion recommending the extension of indication 
for STIVARGA® (regorafenib) for the treatment of adult patients with HCC who have been previously 
treated with sorafenib. In March 2017, the MAH of STIVARGA® (Bayer) requested EUnetHTA to 
perform a relative assessment of the effectiveness and safety of regorafenib in this new indication. 
The aim of this report is to provide a common assessment basis that can be used by European 
HTA bodies for their national appraisal of reimbursement decisions. 
Like sorafenib, regorafenib is an oral antineoplastic agent that potently blocks multiple protein ki-
nases, including kinases involved in tumour angiogenesis, oncogenesis and the tumour microenvi-
ronment. Its chemical structure differs from sorafenib by the addition of one fluorine atom. Regoraf-
enib has been previously granted marketing approval for the treatment of adult pretreated patients 
with mCRC and unresectable or metastatic GIST2. 
HCC is the most common type of liver cancer. Its incidence varies from 3 out of 100,000 in western 
countries to more than 15 out of 100,000 in certain areas of the world [7]. Cirrhosis of various 
aetiologies (HCV, HBV, alcohol use) is the largest risk factor for HCC associated with 80–90% of 
all cases. As the prognosis of patients with HCC is generally poor, it represents the third-leading 
cause of cancer-related death in the world. When diagnosed at an early stage, patients may gen-
erally be eligible for curative treatments mainly represented by surgical resection, radiofrequency 
ablation or liver transplantation. When diagnosed at an intermediate stage (multinodular) or for pa-
tients who progress to an intermediate stage, TACE is generally the preferred option. For patients 
diagnosed with an advanced tumour or for those who progress to an advanced disease, therapeutic 
management depends on the general state. Sorafenib is the standard systemic therapy indicated 
for patients with a well-preserved liver function (Child-Pugh A) and a good performance status 
(ECOG 0-1) with the objective to increase survival but not to cure the disease. There is little evi-
dence to support the use of sorafenib in Child-Pugh B patients. Although it can be recommended 
by some scientific societies, with a low strength of evidence sorafenib faces some reimbursement 
restriction in Child-Pugh B patients3. For patients with a Child-Pugh C status or a PS >2 (or 
ECOG>1) only BSC with symptomatic treatment are recommended. Patients who progress on or 
after sorafenib treatment are only eligible for BSC as no other treatment is currently approved or 
recommended in this situation, emphasising a medical need in the population scoped in this report. 
This REA is based on a pivotal, randomised, double-blind phase III trial sponsored by the MAH 
comparing regorafenib (160 mg by mouth once daily in a 3/1 schedule) plus BSC versus placebo 
plus BSC in patients with HCC who had progressed while on sorafenib: the RESORCE trial [33]. 
The overall design of this pivotal trial is appropriate with a low risk of bias; the authors conducted a 
risk of bias assessment on a study and outcome level for RCTs. As previously stated, no treatments 
are currently approved or recommended for patients previously treated with sorafenib; therefore, 
placebo plus BSC is considered to be an acceptable comparator. However, the population included 
in this trial was restricted to those who tolerated sorafenib treatment defined as not less than 
20 days at a minimum daily dose of 400 mg once daily within the last 28 days prior to withdrawal 
and to those with a well-preserved general state (ECOG 0-1; Child-Pugh A). Hence, the population 
included in the RESORCE trial represents only a subgroup of the scoped population. The primary 
endpoint was OS. Secondary endpoints included: PFS, objective tumour response rate, median 
DOR and HRQoL (EQ-5D and FACT-hep). In accordance with dedicated reviewers, authors and 
co-authors selected OS and HRQoL as critical efficacy outcomes in this disease and PFS as an 
important efficacy outcome. Conclusions on PFS and HRQoL are, however, limited in the absence 
of adjustment for multiplicity analysis performed in the trial. 
Overall, 573 patients were randomised in the RESORCE trial: 379 in the regorafenib group and 194 
in the placebo group. Demographic and baseline disease characteristics were balanced across both 
treatment arms. The mean age was approximately 63 years in both treatment groups. At study 
entry, most of the patients had an ‘advanced’ BCLC stage (88.7% in the placebo group and 85.8% 
                                            
2 See summary of product characteristics for exact indications. 
3 Restricted to Child-Pugh A in France and Italy. Restricted to Child-Pugh A, adequate renal and hematopoietic functions in 
Croatia. 
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in the regorafenib group), an ECOG performance score of 0 (65% and 67%) and 1 or 2 target 
lesions (mRECIST) (63.9% and 61.4%). The vast majority of the patients included had a Child-Pugh 
A score (97–98%). Most frequent aetiologies of HCC were: hepatitis B (37.7% in the regorafenib 
group and 37.6% in the placebo group), hepatitis C (20.6% and 21.1%) and alcohol use (23.8% 
and 28.4%). As HCC in western countries is mostly caused by alcohol use, hepatitis C (although 
this is tending to decrease) and obesity, the RESORCE population does not fully reflect the Euro-
pean population. However, this potential limit is not considered to have an impact on trial validity. 
This study met its primary endpoint: the median OS time was 10.6 months (95% CI 9.1, 
12.1 months) in the regorafenib group and 7.8 months (95% CI 6.3, 8.8 months) in the placebo 
group, corresponding to an absolute gain of 2.8 months in favour of regorafenib: HR=0.627 (95% 
CI 0.500, 0.785), one sided p-value =0.000020. 
The addition of regorafenib to BSC was also superior in terms of PFS: 3.1 months (95% CI 2.8, 4.2) 
versus 1.5 months (95% CI 1.4, 1.6) corresponding to an absolute gain of 1.6 months: HR=0.455 
(95% CI 0.371, 0.558), p<0.000001. 
Regarding safety, more Grade ≥3 AEs were seen in the regorafenib group than in the placebo 
group: 51.9% versus 17.6%. Similarly, SAE rates were higher in the regorafenib group: 10.4% ver-
sus 2.6%. Dose modifications due to AEs (interruption or reduction) were more frequently required 
in the regorafenib group (68.2%) than in the placebo group (31.1%). 
The most frequent drug-related Grade 3 AEs in the regorafenib group were: hypertension (12.8%), 
HFSR (12.3%), blood bilirubin increased (5.1%), AST increased (4.5%) and hypophosphataemia 
(4.3%). Important risks identified in the RMP (all indications) were: severe drug-induced liver injury, 
cardiac ischaemic events, hypertension and hypertensive crisis, haemorrhage, HFSR, PRES, gas-
trointestinal perforation and fistulae, SJS and TEN. 
The exploratory analysis of HRQoL as measured by the EQ-5D and FACT-hep scales suggested 
the absence of a clinically relevant difference between the two study groups for these criteria. How-
ever, an important amount of missing data was observed (about 50% of the patients were evaluated 
at the end of treatment) limiting the conclusion on HRQoL. Furthermore, in a less selected popula-
tion more representative of patients seen in a real-life setting, given the safety profile of this drug, 
regorafenib is likely to have an impact on patients’ quality of life. 
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10 CONCLUSION 
The market authorisation of regorafenib was recently extended to the treatment of patients with 
HCC who have been previously treated with sorafenib. So far, no active drug was authorised or 
used in clinical practice in these patients, emphasising a high unmet medical need in the scoped 
population. 
This extension of indication is based on a single randomised pivotal trial (the RESORCE study), 
which demonstrated that regorafenib plus BSC is more effective than placebo plus BSC in terms of 
OS in a highly selected group of patients previously treated with sorafenib, who had a preserved 
general state (ECOG 0 or 1), a well-preserved liver function (Child-Pugh A) and who tolerated so-
rafenib4. However, the addition of regorafenib to BSC induced a modest gain in terms of OS 
(+2.8 months in median) at the expense of a worsened safety profile, notably in terms of Grade ≥3 
drug-related AEs, drug-related SAEs and dose reduction or discontinuation due to AEs. Given the 
amount of missing data and the absence of adjustment for multiple analyses, there is insufficient 
evidence to determine the relative impact of regorafenib on HRQoL in comparison with placebo. As 
clinical management of end-stage patients must aim to improve or maintain quality of life, this is 
particularly regrettable. 
In addition, it is important to point out that no data are available in patients who progressed on 
sorafenib treatment but did not tolerate sorafenib or with a deteriorated general state (ECOG >1) or 
a Child-Pugh score of B (not eligible for the RESORCE trial) or a combination of these; hence, the 
clinical benefit of regorafenib cannot be assessed in these fragile populations. Given the broad 
marketing authorisation wording (indicated as monotherapy for the treatment of adult patients with 
HCC who have been previously treated with sorafenib), further research or data collection are 
deemed necessary to evaluate the use of regorafenib in these specific subgroups. 
 
                                            
4 Defined as not less than 20 days at a minimum daily dose of 400 mg once daily within the last 28 days prior to withdrawal. 
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APPENDIX 1: METHODS AND DESCRIPTION OF THE EVIDENCE USED 
 
DOCUMENTATION OF THE SEARCH STRATEGIES 
 
Search Strategy (done by the MAH) 
ProQuest 
Table A1: Search terms in ProQuest 
Topic Search 
number 
Search String 
Result hits 
(10/01/2017) 
HCC S1 TI,AB((hepatic OR liver) AND cell AND (cancer OR carcinoma OR neo-
plasm)) 
99975* 
S2 TI,AB(malignant NEAR/3 hepatoma) 398° 
S3 TI,AB(hepatocarcinoma OR "hepatocellular carcinoma" OR "HCC ") 168566* 
S4 TI,AB(HCC) 97375* 
S5 EMB.EXACT("liver cell carcinoma") 125648* 
S6 MESH.EXACT("Carcinoma, Hepatocellular") 68082* 
S7 S1 OR S2 OR S3 OR S4 OR S5 OR S6 298802* 
Intervention S8 TI,AB(regorafenib) 887° 
S9 TI,AB(Stivarga) 32° 
S10 TI,AB("bay 73 4506" OR "bay 73-4506" OR "bay 734506" OR "bay73 
4506" OR "bay73-4506" OR "bay734506") 
44° 
S11 EMB.EXACT("regorafenib") 1533° 
 S12 S8 OR S9 OR S10 OR S11 1612* 
Total S13 S7 AND S12 217° 
* Duplicates are removed from the search, but included in the result count. 
° Duplicates are removed from the search and from the result count. 
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Cochrane 
Table A2: Search terms in the Cochrane Library 
Search 
Type 
Search 
Number 
Search String Result hits 
(10/01/2017) 
HCC 
 #1 
MeSH descriptor: [Carcinoma, Hepatocellular] explode all 
trees 
1308 
#2 “HCC”: ti,ab,kw 
1307 
#3 "hepatic cell carcinoma":ti,ab,kw 
2 
#4 "hepatic cell cancer":ti,ab,kw  
1 
#5 "liver cell carcinoma":ti,ab,kw 
899 
#6 “liver cell cancer":ti,ab,kw 
2 
#7 "hepatocarcinoma":ti,ab,kw 
45 
#8 "hepatocellular carcinoma":ti,ab,kw 
2219 
#9 
malignant near/3 hepatoma:ti,ab,kw 4 
#10 
#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR 
#9 
2762 
#11 "Regorafenib":ti,ab,kw 117 
#12 "Stivarga":ti,ab,kw 3 
#13 #11 OR #12 117 
#14 #10 AND #13 3 
Results by 
database  Cochrane Database of Systematic Reviews (CDSR) 
0 
  Database of Abstracts of Reviews of Effects (DARE) 0 
 
 
Cochrane Central Register of Controlled Trials (CEN-
TRAL) 
2 
  Cochrane Methodology Register (CMR) 0 
  Health Technology Assessments Database (HTA) 1 
  NHS Economic Evaluations Database (EED) 0 
  Cochrane Groups 0 
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Conferences 
Table A3: Search terms in Conference websites and clinicaltrials.gov 
Organization Search string Results hits (16/01/2017) 
American Association for Cancer 
Research (AACR) 
“hepatocellular carcinoma”; “HCC”; 
"regorafenib” 
4 
American Society of Clinical On-
cology (ASCO) 
"hepatocellular carcinoma" AND "regoraf-
enib" 
1 
ASCO Gastrointestinal Cancers 
Symposium (ASCO GI) 
"hepatocellular carcinoma" AND "regoraf-
enib" 
0 
European Society for Medical On-
cology (ESMO)  
"hepatocellular carcinoma" AND "regoraf-
enib" 
4 
International Liver Cancer Asso-
ciation (ILCA) 
"regorafenib"* 0** 
European Society of Digestive 
Oncology (ESDO)  
“hepatocellular carcinoma”; “HCC”* 0 
European Association for the 
Study of the Liver (EASL)  
“hepatocellular carcinoma” AND "regoraf-
enib" 
1 
ESMO World Congress on Gas-
trointestinal Cancer (WCGIC) 
"hepatocellular carcinoma"; “HCC”; 
"regorafenib"* 
92 
Japanese Society of Medical On-
cology (JSMO) 
“hepatocellular carcinoma” AND "regoraf-
enib"  
3 
Chinese Society of Clinical On-
cology (CSCO) 
“hepatocellular carcinoma”; “HCC”; 
"regorafenib”* 
0 
American Association for the 
Study of Liver Diseases (AASLD) 
“hepatocellular carcinoma” AND "regoraf-
enib" 
3 
Clinicaltrials.gov "hepatocellular carcinoma" AND "regoraf-
enib" 
3 
*No search engine function was available to search for relevant abstracts, therefore search term was limited to "hepa-
tocellular carcinoma" 
**Only 2016 abstract book meeting is accessible, abstract books for 2015 and 2014 were not available online. 
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Studies for full-text selection 
Table A4: References screened during full-text selection 
Authors Journal Title Final de-
cision FT 
Comment 
Bolondi, Tak et al. 
(2011)  
European Journal 
of Cancer (2011), 
47, S464 
Phase II safety study of the oral multikinase inhibitor regorafenib ( BAY 73-4506 
) as second-line therapy in patients with hepatocellular carcinoma 
Excluded, 
did not 
meet 
study de-
sign crite-
ria 
 
Ravi and Singal (2014) Core Evidence 
(2014) 9, 81-87 
Regorafenib: An evidence-based review of its potential in patients with advanced 
liver cancer 
Excluded, 
did not 
meet 
study de-
sign crite-
ria 
 
(Bruix, Merle et al. 
2016a) 
Annals of Oncology 
(2016), 27 
Efficacy, safety, and health-related quality of life (HRQoL) of regorafenib in pa-
tients with hepatocellular carcinoma (HCC) progressing on sorafenib: Results of 
the international, double-blind phase 3 RESORCE trial 
Included  
(Bruix, Tak et al. 2013) European Journal 
of Cancer (2013), 
49, (16) 3412-3419 
Regorafenib as second-line therapy for intermediate or advanced hepatocellular 
carcinoma: Multicentre, open-label, phase II safety study 
Excluded, 
did not 
meet 
study de-
sign crite-
ria 
 
(Bruix, Merle et al. 
2016) 
Annals of Oncology 
(2016), 27, ii140-
ii141 
Efficacy and safety of regorafenib versus placebo in patients with hepatocellular 
carcinoma (HCC) progressing on sorafenib: Results of the international, random-
ized phase 3 RESORCE trial 
Included  
(Bruix, Qin et al. 2017) The Lancet (2017) Regorafenib for patients with hepatocellular carcinoma who progressed on soraf-
enib treatment (RESORCE): A randomized, double-blind, placebo-controlled, 
phase 3 trial 
Included  
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Authors Journal Title Final de-
cision FT 
Comment 
Yu, Su et al. (2016) IEEE/ACM trans-
actions on compu-
tational biology and 
bioinformatics 
(2016) 
Prediction of novel drugs for hepatocellular carcinoma based on multi-source ran-
dom walk 
Included  
Cheng, Finn et al. 
(2013) 
Journal of Clinical 
Oncology (2013), 
31 (15) 
Regorafenib (REG) in patients with hepatocellular carcinoma ( HCC ) progressing 
following sorafenib: An ongoing randomized, double-blind, phase III trial 
Excluded, 
did not 
meet the 
outcome 
criteria  
No outcomes 
were reported 
(poster, regard-
ing study design 
of RESORCE) 
Bruix, Finn et al. (2014)5 Journal of Clinical 
Oncology (2014), 
32 (15) 
RESORCE: An ongoing randomized, double-blind, phase III trial of regorafenib 
(REG) in patients with hepatocellular carcinoma ( HCC ) progressing on sorafenib 
(SOR) 
Excluded, 
did not 
meet the 
outcome 
criteria  
No results were 
reported (only 
study design of 
RESORCE) 
Ribeiro de Souza, Reig 
et al. (2016) 
Expert Opinion on 
Pharmacotherapy 
(2016), 17 (14), 
1923-1936 
Systemic treatment for advanced hepatocellular carcinoma : the search of new 
agents to join sorafenib in the effective therapeutic armamentarium 
Excluded, 
did not 
meet the 
outcome 
criteria  
No results were 
reported (review) 
Woo, Yoo et al. (2017) Expert Opinion on 
Pharmacotherapy 
(2017), 18 (1), 35-
44 
New chemical treatment options in second-line hepatocellular carcinoma : what 
to do when sorafenib fails? 
Included  
Trojan and Waidmann 
(2016) 
Journal of hepato-
cellular carcinoma 
(2016), 3 31-36 
Role of regorafenib as second-line therapy and landscape of investigational treat-
ment options in advanced hepatocellular carcinoma 
Included  
von Felden, Schulze et 
al. (2016) 
Diagnostics (Basel, 
Switzerland) 
(2016), 6 (4) 
First- and Second-Line Targeted Systemic Therapy in Hepatocellular Carcinoma 
-An Update on Patient Selection and Response Evaluation 
Included  
                                            
5 Found twice in the systematic literature review (one abstract and one poster) 
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Authors Journal Title Final de-
cision FT 
Comment 
(Bruix 2016) Hepatic Oncology 
(2016), 3 (3), 187-
189 
Regorafenib and the RESORCE trial: A new second-line option for hepatocellular 
carcinoma patients 
Excluded, 
did not 
meet the 
study de-
sign crite-
ria  
Interview 
Kudo (2016) Liver Cancer 
(2016), 5, 1 
Recent advancement in HCC treatment Excluded, 
did not 
meet the 
outcome 
criteria  
No results were 
reported (presen-
tation, without 
references) 
Abou-Alfa (2016) Liver Cancer 
(2016), 5, 43 
An odyssey from doxorubicin to nivolumab with sorafenib and regorafenib in be-
tween 
Excluded, 
did not 
meet the 
outcome 
criteria  
No results were 
reported (no ref-
erences) 
Killock (2017) Nature reviews. 
Clinical oncology 
(2016) 
Liver cancer: Regorafenib - a new RESORCE in HCC Included  
Finn (2016) Liver Cancer 
(2016), 5, 7 
Highlights on targeted therapy for HCC Excluded, 
did not 
meet the 
outcome 
criteria  
No results were 
reported (no ref-
erences) 
US National Institutes of 
Health (2016) 
Clinicaltrials.gov 
(2016) 
Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma Included  
US National Institute of 
Health (2015) 
Clinicaltrials.gov 
(2015) 
Safety Study of BAY73-4506 in Patients With Hepatocellular Carcinoma Excluded, 
did not 
meet 
study de-
sign crite-
ria 
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DESCRIPTION OF THE EVIDENCE USED  
 
Guidelines for diagnosis and management  
 
Table A5: Overview of guidelines 
Name of 
society/organisation 
issuing guidance 
Date of 
issue 
Country/ies  
to which 
applicable 
Summary of recommendation and Level of 
evidence (A,B,C) / class of recommendation (I, 
IIa, IIb, III) 
EASL-EORTC (Llovet 
2012) 
2012 Europe  First Line treatment: 
 Anatomical resections are recommended for 
patients with solitary tumors and very well pre-
served liver function (normal bilirubin with he-
patic venous pressure gradient ≤10 mmHg or 
platelet count ≥100, 000). (3A/2C)  
 Liver transplantation is considered for patients 
with single tumors less than 5 cm or ≤3 nodules 
≤3 cm (Milan criteria) not suitable for resection. 
(2A/1A) 
o Neo-adjuvant treatment can be considered 
for loco-regional therapies if the waiting list 
exceeds 6 months due to good cost-effec-
tiveness data and tumor response rates, 
even though impact on long-term outcome 
is uncertain. (2D/2B) 
o Living donor liver transplantation is an al-
ternative option in patients with a waiting 
list exceeding 6-7 months, and offers a 
suitable setting to explore extended indica-
tions within research programs. (2A/2B) 
o Down-staging policies for HCCs exceeding 
conventional criteria cannot be recom-
mended and should be explored in the 
context of prospective studies aimed at 
survival and disease progression. (2D/2C) 
Local ablation for BCLC 0-A tumors not suitable for 
surgery: 
 Radiofrequency ablation is recommended in 
most cases where the tumors are less than 5 
cm due to a significantly better control of the 
disease. (1iD/1A) 
 Ethanol injection is recommended in cases 
where radiofrequency ablation is not technically 
feasible (around 10-15%) 
Chemoembolization and transcatheter therapies: 
 Chemoembolization is recommended for pa-
tients with BCLC stage B, multinodular asymp-
tomatic tumors without vascular invasion or ex-
tra-hepatic spread. (1iiA/1A) 
 Chemoembolization is discouraged in patients 
with decompensated liver disease, advanced 
liver dysfunction, macroscopic invasion or extra-
hepatic spread. (1iiA/1B) 
 Bland embolization is not recommended 
 Internal radiation with 131I or 90Y glass beads not 
recommended as standard therapy. (2A/2B) 
 Selective intra-arterial chemotherapy or lipiodo-
lization are not recommended. (2A/2B) 
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Name of 
society/organisation 
issuing guidance 
Date of 
issue 
Country/ies  
to which 
applicable 
Summary of recommendation and Level of 
evidence (A,B,C) / class of recommendation (I, 
IIa, IIb, III) 
Systemic therapies: 
 Sorafenib is indicated for patients with well-pre-
served liver function (Child-Pugh A class) and 
with advanced tumors (BCLC C) or those tu-
mors progressing upon loco-regional therapies. 
(1iA/1A) 
 Systemic chemotherapy, tamoxifen, immuno-
therapy, antiandrogen, and herbal drugs are not 
recommended for the clinical management of 
HCC patients. 1-2A/1A/B) 
 BSC or the inclusion of patients in clinical trials 
is recommended for patients with intolerance or 
failure to sorafenib. (Recommendation 2B) 
 In specific circumstances, radiotherapy can be 
used to alleviate pain in patients with bone me-
tastasis (3A/2C) 
Palliative support including management of pain, 
nutrition and psychological support should be 
rendered to patients at BCLC D stage  
ESMO-ESDO (Verslype 
2012) 
2012 Europe For use of radical therapies for management of lo-
calized disease: 
 Resection is recommended for patients without 
advanced fibrosis, as long as an R0 resection 
can be carried out without causing postopera-
tive liver failure due to a too small liver remnant  
(III/B) 
 In the case of cirrhosis, resection is effective 
and safe in early BCLC stages (0 and A) pro-
vided that one is dealing with a single lesion, a 
good performance status and no clinically im-
portant portal hypertension (III/B) 
 For patients with small nodules <2 cm, BCLC 
stage 0 or those in early stages that are not 
candidates for resection, RFA and PEI can be 
considered alternatives to resection (III/B) 
 RFA provides better local control than PEI, es-
pecially in HCCs >2 cm (II/A) 
 The number and diameter of lesions treated by 
RFA should not exceed five and 5 cm, respec-
tively (III/B) 
 Neo-adjuvant or adjuvant therapies are not rec-
ommended to improve outcome of patients 
treated with resection or local ablation (II/B) 
 Liver transplantation should be considered in 
patients with a solitary lesion of <5 cm or three 
nodules <3 cm that are not suitable for resec-
tion (II/A) 
 In the case of a long anticipated waiting time 
(>6 months) for liver transplant, patients may be 
offered resection, local ablation or TACE trans-
arterial chemoembolization in order to minimise 
the risk of tumor progression and to offer a 
‘bridge’ to transplant (III/B) 
For use of palliative treatments for management of 
locally advanced/metastatic disease:  
 TACE is recommended for patients with BCLC 
stage B, or those with an excellent liver function 
and multinodular asymptomatic tumors without 
macroscopic vascular invasion or extra hepatic 
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Name of 
society/organisation 
issuing guidance 
Date of 
issue 
Country/ies  
to which 
applicable 
Summary of recommendation and Level of 
evidence (A,B,C) / class of recommendation (I, 
IIa, IIb, III) 
spread (I/A) 
 The combination of TACE with systemic agents 
such as sorafenib—either sequential or con-
comitant—cannot be recommended today in 
clinical practice 
 Sorafenib is recommended for patients with ad-
vanced HCC and well-preserved liver function 
(BCLC stage C) and those with intermediate-
stage HCC who progress following TACE (I/A) 
 In the case of progression or intolerance to so-
rafenib, BSC is preferred or patients should be 
included in clinical trials 
 Systemic chemotherapy, tamoxifen, immuno-
therapy, anti-androgen or somatostatin ana-
logues are not recommended for the clinical 
management of HCC patients (I–II/A–B) 
For patients with end-stage disease with heavily 
impaired liver function or a poor performance 
status (both due to the tumor involvement of the 
liver), only symptomatic treatment is advocated, as 
they will die within 6 months (III/B) 
NCCN  Update 
May 
2017 
United 
States 
 Section Unresectable HCC (HCC-5): 
 Evaluation whether patient is a candidate for 
transplant (UNOS criteria HCC-4) 
 Not a transplant candidate: 
o Locoregional therapy 
(Ablation, Arterially directed therapies, 
EBRT) 
o Systemic therapy  
 sorafenib, Child-Pugh Class 
A or B 
 chemotherapy 
o Clinical trial 
o Best supportive care 
 Regorafenib if progression on or after sorafenib 
(Child-Pugh Class A only)(Category 1) 
 Section Local disease, metastatic disease, 
extensive liver burden (HCC-6): 
 Inoperable, local disease or Local disease with 
minimal extrahepatic disease only (HCC-6): 
o Locoregional therapy 
(Ablation, Arterially directed therapies, 
EBRT) 
o Systemic therapy  
 sorafenib, Child-Pugh Class 
A or B 
 chemotherapy 
o Clinical trial 
o Best supportive care 
 Regorafenib if progression on or after sorafenib 
(Child-Pugh Class A only) (Category 1) 
  
 Metastatic disease or extensive liver tumor bur-
den (HCC-6): 
o Systemic therapy  
 sorafenib, Child-Pugh Class 
A or B 
 chemotherapy 
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Name of 
society/organisation 
issuing guidance 
Date of 
issue 
Country/ies  
to which 
applicable 
Summary of recommendation and Level of 
evidence (A,B,C) / class of recommendation (I, 
IIa, IIb, III) 
o Clinical trial 
o Best supportive care 
 Regorafenib if progression on or after sorafenib 
(Child-Pugh Class A only) (Category 1) 
(note: NCCN discussion section update is in 
progress) 
LAASL (Méndez-
Sánchez 2014) 
2014 Latin 
America 
 Indicates liver transplant as first line treatment 
for patients within Malian criteria (single tumor 
criteria ≤5 cm or ≥ nodules ≤3 cm) and not suit-
able for resection. Class of evidence 1, level of 
evidence A 
 Liver transplant may be considered after suc-
cessful downstaging to meet the Malian criteria. 
Class of evidence 2a, level of evidence B 
 Indicates resection for patients with solitary 
nodular tumor and preserved liver function; tu-
mor size, presence of satellite lesions, and vas-
cular involvement should be considered. Class 
of evidence 2a, level of evidence B 
 In patients with esophageal varices, diuretic 
therapy to control ascites, and high bilirubin 
level should not be considered for resection. 
Class of evidence 2a, level of evidence B 
 Resection margins should aim for >2 cm mar-
gins, except in patients with reduced parenchy-
mal reserve. Class of evidence 3, level of evi-
dence B 
 For patients with BCLC 0-A not suitable for sur-
gery, the standard of care is local ablation with 
RFA or PEI. Class of evidence 2a, level of evi-
dence B 
 Indicates RFA for tumors <5 cm, and PEI in 
cases where RFA is technically not feasible 
(about 10 to 15% of patients). Class of evidence 
1, level of evidence A 
 Indicates chemoembolization for patients with 
BCLC stage B without portal invasion. Class of 
evidence 1, level of evidence A 
 Preoperative TACE should not be considered 
the standard of care. Class of evidence 1, level 
of evidence A 
 Indicates sorafenib as the standard systemic 
treatment for HCC patients with child-Pugh 
class A underlying cirrhosis and advanced tu-
mor (BCLC stage C) or tumor progression after 
locoregional therapy.  Class of evidence 1, level 
of evidence A 
 No alternative treatment for patients with intoler-
ance or failure to respond to sofafenib. Class of 
evidence 2, level of evidence B 
Abbreviations: ADT - arterially directed therapies; BCLC - Barcelona Clinic Liver Cancer; BSC - Best supportive care; 
DEB – drug-eluting beads; EASL-EORTC - European Association for the Study of the Liver, European Organisation for 
Research and Treatment of Cancer; EBRT - external beam radiation therapy; ESMO–ESDO – European Society for 
Medical Oncology, European Society of Digestive Oncology; HCC – hepatocellular carcinoma; IMRT -  intensity modulated 
radiation therapy; LAASL - Latin American Association for the Study of the Liver; PBT – proton beam therapy; PEI - 
percutaneous ethanol injection; RE -  radioembolisation; RFA - radiofrequency ablation; SBRT -  stereotactic body 
radiation therapy; TACE - transarterial chemoembolization; TAE -  transarterial bland embolization; UNOS, United Network 
for Organ Sharing 
Sources:  
EASL- EORTC  
ESMO – ESDO  
LAASL  
NCCN  
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Evidence tables of individual studies included for clinical effectiveness and 
safety 
 
Table A6: Characteristics of randomised controlled studies 
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): 
a randomised, double-blind, placebo-controlled, phase 3 trial 
Study identifier NCT01774344, RESORCE 
Design randomised, double-blind, placebo-controlled phase III trial 
  
First subject first visit: May 14, 2013 
Last subject Last visit February 29, 2016 
Hypothesis Superiority  
Treatments groups 
 
 
Regorafenib plus BSC 
 
160 mg (4 x 40 mg tablets) orally (p.o.) 
every day for 3 weeks followed by 1 week 
off treatment (schedule 3/1) plus BSC; N= 
379 
Placebo plus BSC 4 matching placebo tablets with a 3/1 
schedule plus BSC; N= 194 
Endpoints and definitions 
 
Primary 
endpoint 
 
OS 
Time from the date of randomisation to 
death due to any cause 
Secondary 
endpoint 
PFS Time (days) from date of randomization to 
date of disease progression (radiological or 
clinical) or death due to any cause, if death 
occurs before progression is documented 
Exploratory 
endpoint 
HRQoL Assessed using the FACT-Hep and the 
EQ-5D questionnaires 
Database lock August 5, 2016 
Results and Analysis  
Analysis description Primary Analysis 
Analysis population and 
time point description 
Intent to treat 
Descriptive statistics and 
estimate variability 
Treatment group regorafenib placebo 
Number of subject 379 194 
Primary endpoint 
OS 
(median, months) 
 
10.6  
 
7.8  
(95 % CI) (9.1, 12.1) (6.3, 8.8) 
PFS 
(median, months) 
3.1  1.5  
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Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): 
a randomised, double-blind, placebo-controlled, phase 3 trial 
Study identifier NCT01774344, RESORCE 
(95 % CI) (2.8, 4.2) (1.4, 1.6) 
EQ-5D index 0.76 0.77 
(95 % CI) (0.75; 0.78) (0.75, 0.79) 
EQ-5D VAS 71.68 73.45 
(95 % CI) (70.46; 72.90) (71.84, 75.06) 
FACT-hep 129.31  133.17 
(95 % CI) (127.84; 130.79) (131.21, 135.12) 
Effect estimate per com-
parison 
Primary endpoint 
OS 
Comparison groups Regorafenib vs placebo 
Hazard ratio 0.627 
95%CI 
0.500, 0.785 
One-sided p-value p<0.0001 
Secondary endpoint 
PFS (mRECIST) 
Comparison groups Regorafenib vs placebo 
Hazard ratio 0.455  
95%CI 0.371, -0.558 
One-sided p-value p<0.000001 
Exploratory endpoint 
Exploratory endpoint 
EQ-5D index 
(LSM time-adjusted 
AUC) 
Comparison groups  Regorafenib vs placebo 
Difference -0.01 
95%CI -0.03, 0.02 
One-sided p-value 0.47 
Exploratory endpoint 
EQ-5D VAS 
(LSM time-adjusted 
AUC) 
Comparison 
groups  
Regorafenib vs placebo 
Difference -1.77 
95%CI -3.58, 0.04 
One-sided p-value 0.06 
 
Exploratory endpoint 
FACT-hep 
(LSM time-adjusted 
AUC) 
Comparison 
groups  
Regorafenib vs placebo 
Difference -3.85 
95%CI -6.06, -1.65 
One-sided p-value 0.0006 
Notes  
This study was conducted in a selected population with a preserved general 
state, a Child-Pugh score of A and who tolerated sorafenib treatment (cf 
inclusion/exclusion criteria). 
 
Given the number of missing data observed (about 50% of the patients were 
evaluated at the end of treatment) and the exploratory nature of HRQoL, no 
formal conclusion can be made on this critical outcome. 
 
Abbreviations: CI=confidence interval; HRQoL=health-related quality of life; OS=overall survival; PFS=progression-free 
survival; ORR=overall response rate. 
Sources: clinical study report. 
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List of ongoing and planned studies 
 
Table A7: List of ongoing studies with regorafenib 
Study Identifier Time Study type Number 
of pa-
tients 
Intervention Com-
para-
tor 
Patient population Endpoints 
NCT02664077 
Actively recruit-
ing 
Study Start 
Date: June 
2016  
Estimated 
Study Comple-
tion Date: Jan-
uary 2025  
Estimated Pri-
mary Comple-
tion Date: No-
vember 2023 
Interventional; 
Phase 3 
Esti-
mated  
Enroll-
ment: 
1118 
Regorafenib (orally once 
daily for 21 days of a 28 
day cycle for a total of 26 
cycles) 
Pla-
cebo 
Patients with Stage III (IIIB or IIIC) 
colon cancer are randomized 1:1 to 
placebo or the experimental agent 
regorafenib following completion of at 
least four months of standard adju-
vant therapy (e.g. 5-fluorouracil, leu-
covorin, oxaliplatin (FOLFOX) , cape-
citabine, oxaliplatin (CapeOx), and 
other). 
Primary Outcome Measures: 
DFS 
Secondary Outcome 
Measures: OS, toxicity, com-
pliance, tolerability, biomarker, 
PK 
NCT02106858 
Actively recruit-
ing 
Actual Study 
Start Date: 
25/06/2014  
Estimated 
Study Comple-
tion Date: 
07/05/2019  
Observational; 
Post-Marketing 
Surveillance 
Esti-
mated 
enrol-
ment: 
190 
regorafenib under ap-
proved local prescriptions 
None Patients diagnosed with metastatic 
colorectal cancer or metastatic or un-
resectable locally advanced GISTby 
physician. 
Primary Outcome Measures: 
Percentage of patients with 
serious adverse events 
  
Secondary Outcome 
Measures: Overall response, 
PFS, OS 
PTJA02 - Regorafenib indicated as monotherapy for the treatment of adult patinets with Hepatocellular carcinoma who have been previously treated with Sorafenib 
 
Version 1.2, October 2017 EUnetHTA Joint Action 3 WP4 69 
Study Identifier Time Study type Number 
of pa-
tients 
Intervention Com-
para-
tor 
Patient population Endpoints 
Estimated Pri-
mary Comple-
tion Date: 
07/05/2019  
NCT01933958 
Actively recruit-
ing 
Actual Study 
Start Date: 
04/09/2013  
Estimated 
Study Comple-
tion Date: 
25/06/2021  
Estimated Pri-
mary Comple-
tion Date: 
25/06/2021  
Regulatory 
post-marketing 
surveillance in 
Japan, and it is 
a local prospec-
tive and obser-
vational study 
Esti-
mated 
enrol-
ment: 
135 
Regorafenib under practi-
cal manner for gastrointes-
tinal stromal tumors pro-
gressed after cancer 
chemotherapy. 
None Patients who have received Regoraf-
enib for GIST progressed after can-
cer chemotherapy. 
Primary Outcome Measures: 
Number of patients with ad-
verse drug reactions  
Secondary Outcome 
Measures: OS, TTF, tumour 
response, safety 
 
NCT02042144 
On-going not 
recruiting 
Actual Study 
Start Date: 
08/04/2014  
Estimated 
Study Comple-
tion Date: 
01/12/2017  
 
Observational Enroll-
ment: 
1031 pa-
tients 
Regorafenib None Patients with mCRC who have been 
previously treated with other ap-
proved treatments for metastatic dis-
ease and for whom a decision has 
been made by the physician to treat 
with regorafenib according to local 
health authority approved label. 
Primary Outcome Measures: 
Incidence of TEAE 
Secondary Outcome 
Measures: OS, PFS, DCR, 
HRQoL, healthcare resource 
utilisation 
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Study Identifier Time Study type Number 
of pa-
tients 
Intervention Com-
para-
tor 
Patient population Endpoints 
Estimated Pri-
mary Comple-
tion Date: 
30/09/2017  
NCT01843400 
On-going not 
recruiting 
Actual Study 
Start Date: 
22/04/2013  
Estimated 
Study Comple-
tion Date: 
24/03/2021  
Primary Com-
pletion Date: 
12/09/2016  
Regulatory 
post-marketing 
surveillance in 
Japan; local 
prospective and 
observational 
study. 
Enroll-
ment: 
1306 pa-
tients 
Regorafenib  None Patients with unresectable, meta-
static or recurrent colorectal cancer 
Primary Outcome Measures 
Number of patients with ad-
verse drug reactions ADRs 
and SAEs  
Secondary Outcome 
Measures: Determination of 
patient's background to affect 
the safety and efficacy of 
Regorafenib using standard 
observational survey and fol-
low-up survey  
NCT01853319 
On-going not 
recruiting 
Actual Study 
Start Date: 
24/07/2013 
 
Estimated 
Study Comple-
tion Date: 
29/09/2017  
Interventional;  
An Open-label 
Phase III Study 
Enroll-
ment 
100 pa-
tients 
Regorafenib None In patients with mCRC who have pro-
gressed after all approved standard 
therapy. 
Outcome Measures: safety, 
PFS, 
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Study Identifier Time Study type Number 
of pa-
tients 
Intervention Com-
para-
tor 
Patient population Endpoints 
Primary Com-
pletion Date: 
24/04/2015  
NCT01774344 
On-going not 
recruiting 
Actual Study 
Start Date: 
14/05/2013  
Estimated 
Study Comple-
tion 
28/02/2018  
Primary Com-
pletion Date: 
29/02/2016  
Interventional; 
Randomized, 
Double-blind, 
Placebo Con-
trolled, Multi-
center Phase III 
Study 
Enroll-
ment: 
573 pa-
tients 
Regorafenib Pla-
cebo 
Patients with advanced liver cancer 
who have progressed on sorafenib 
treatment. 
Primary Outcome Measures: 
OS  
Secondary Outcome 
Measures: TTP, PFS, ORR, 
DCR 
NCT01271712 
On-going not 
recruiting 
Study Start 
Date:  
January 2011  
Estimated 
Study Comple-
tion Date: De-
cember 2017  
Primary Com-
pletion Date: 
January 2012  
Interventional; 
Randomized, 
double-blind, 
placebo-con-
trolled phase III 
study 
Enroll-
ment: 
199 pa-
tients 
Regorafenib + BSC Pla-
cebo 
+ 
BSC 
Patients with metastatic and/or unre-
sectable GIST whose disease has 
progressed despite prior treatment 
with at least imatinib and sunitinib. 
Primary Outcome 
Measures:PFS  
Secondary Outcome 
Measures: OS, TTP, Tumour 
response, ORR, DCR, DOR 
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Study Identifier Time Study type Number 
of pa-
tients 
Intervention Com-
para-
tor 
Patient population Endpoints 
NCT02465502 
On-going not 
recruiting 
Actual Study 
Start Date: 
21/07/2015 
Estimated 
Study Comple-
tion Date: 
31/07/2017  
Primary Com-
pletion Date: 
02/05/2017  
Interventional; 
Uncontrolled, 
Open-label  
Phase IIb 
Enroll-
ment: 
59 pa-
tients 
Regorafenib None Patients With Antiangiogenic-naive 
and Chemotherapy-refractory Ad-
vanced Colorectal Cancer 
Primary Outcome Measures: 
Percentage of participants 
without disease progression or 
death at the end of 8 weeks  
Secondary Outcome 
Measures: PFS, OS, ORR, 
DCR , safety  
NCT00664326 
On-going not 
recruiting 
Actual Study 
Start Date: 
30/04/2008  
Estimated 
Study Comple-
tion Date: 
18/01/2019  
Primary Com-
pletion Date: 
31/05/2009  
Interventional; 
Uncontrolled, 
open-label, 
non-random-
ized Phase II 
study 
Enroll-
ment: 
49 pa-
tients 
 
Regorafenib None Previously Untreated Patients With 
Metastatic or Unresectable RCC 
Primary Outcome Measures: 
ORR  
Secondary Outcome 
Measures: DCR , OS, PFS, 
TTP, DOR, Duration of Stable 
Disease  
 . 
NCT02085148 
On-going not 
recruiting 
Actual Study 
Start Date: 
11/04/2014  
Interventional; 
Multi-center, 
Open-label, 
Non-random-
ized, Phase I 
Esti-
mated 
Enroll-
ment: 77 
patients 
regorafenib administered 
orally in combination with 
backbone chemotherapy 
(vincristine and irinotecan) 
None Pediatric Patients With Solid Malig-
nant Tumors That Are Recurrent or 
Refractory to Standard Therapy. 
Primary Outcome Measures: 
safety  
Secondary Outcome 
Measures: OS, TTP, ORR, PK 
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Study Identifier Time Study type Number 
of pa-
tients 
Intervention Com-
para-
tor 
Patient population Endpoints 
Estimated 
Study Comple-
tion Date: 
24/10/2019  
Estimated Pri-
mary Comple-
tion Date: 
24/10/2019  
Dose Escala-
tion Study 
 
NCT02106845 
On-going not 
recruiting 
Actual Study 
Start Date: 
22/04/2014  
Estimated 
Study Comple-
tion Date: 
31/12/2017  
Primary Com-
pletion Date: 
27/04/2015  
Interventional 
Phase I, Multi-
center, Non-
randomized, 
Open Label, 
Drug-drug-in-
teraction Study 
Enroll-
ment: 
42 pa-
tients 
Multiple Doses of regoraf-
enib on the Pharmacoki-
netics of Probe Substrates 
of Transport Proteins P-gp 
(Digoxin; Group A) and 
BCRP (Rosuvastatin; 
Group B) 
None Patients With Advanced Solid Malig-
nant Tumors 
Primary Outcome Measures: 
PK 
Secondary Outcome 
Measures: Tumor Response, 
safety 
NCT01973868 
On-going not 
recruiting 
Actual Study 
Start Date: 
21/11/2013  
Estimated 
Study Comple-
tion Date: 
26/10/2017  
Interventional 
Phase 1b, 
Multi-center, 
Non-random-
ized, Open La-
bel, Dose Esca-
lation 
Enroll-
ment: 
44 pa-
tients 
Initial i.v. infusion of cetuxi-
mab (loading dose of 400 
mg/ m2 BSA) on Pre-cycle 
Day -7. 
The treatment of regoraf-
enib in combination with 
cetuximab maintenance 
None In Patients With Locally Advanced or 
Metastatic Solid Tumors Who Are Not 
Candidates for Standard Therapy or 
in Whom Regorafenib or Cetuximab 
is Considered as a Standard Treat-
ment 
Primary Outcome Measures: 
Maximum tolerated dose, 
safety, PK 
Secondary Outcome 
Measures: Tumor response  
PTJA02 - Regorafenib indicated as monotherapy for the treatment of adult patinets with Hepatocellular carcinoma who have been previously treated with Sorafenib 
 
Version 1.2, October 2017 EUnetHTA Joint Action 3 WP4 74 
Study Identifier Time Study type Number 
of pa-
tients 
Intervention Com-
para-
tor 
Patient population Endpoints 
Estimated Pri-
mary Comple-
tion Date: 
10/08/2017 
dose (250 mg/m2 BSA) 
starts on Cycle 1 Day 1. 
Cetuximab infusions will be 
given in a once-weekly 
dosing-regimen as ap-
proved. 
NCT01287598 
On-going not 
recruiting 
Actual Study 
Start Date: 
02/08/2011  
Estimated 
Study Comple-
tion Date: 
29/01/2018  
Estimated Pri-
mary Comple-
tion Date: 
31/12/2017  
Interventional 
Phase I, Non-
randomized 
Open-label 
Study 
Enroll-
ment: 
40 pa-
tients 
Experimental  
Arm 1:  
regorafenib + warfarin + 
omeprazole + midazolam 
Experimental  
Arm 2:  
regorafenib + rosiglitazone 
None Patients With Advanced Solid Tu-
mors 
Primary Outcome Measures: 
PK 
Secondary Outcome 
Measures: Tumor Response 
evaluation, safety 
 
Abbreviations: DFS = disease free survival; PFS= progression free survival, OS = overall survival; TTF= time to treatment failure; TEAE= treatment emergent adverse event, DCR= disease control rate; 
HRQoL= Health related quality of life; ADR= adverse drug reaction; SAE= serious adverse event; AE= adverse event; ORR= objective tumour rate; DCR= disease control rate; DOR= duration of response; 
mCRC= metastatic colorectal cancer; RCC= renal cell cancer; GIST= gastrointestinal stromal cancer, BSC= best supportive care. 
Sources:ClinicalTrial.gov 
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Risk of bias tables 
 
Table A8: Risk of bias – study level (RCTs) 
Trial 
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RESORCE Low Low Uncl
eara 
Uncleara Uncleara Low Low 
comments:  
a Given the safety profile of regorafenib with evocative adverse-events (Hand-foot skin reaction, 
diarrhea, decreased appetite and hypertension notably) blinding could have been broken. 
Abbreviations:  
Sources: Clinical study report 
 
Table A9: Risk of bias – outcome level (RCTs) 
Outcome 
Trial 
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Overall survival 
RESORCE Low  Low Low Low Low 
Progression free survival 
RESORCE Higha b Low Low Low High 
EQ-5D index & VAS 
RESORCE Uncleara Highc Low Low High 
FACT-hep 
RESORCE Uncleara Highc Low Low High 
comments:  
a Given the safety profile of regorafenib with evocative adverse-events (Hand-foot skin reaction, diarrhea, 
decreased appetite and hypertension notably) blinding could have been broken. 
b PFS was assessed by the investigators (absence of independent review committee). 
c substantial number of missing data (about 50% of the patients were evaluated at the end of treatment 
visit) 
Abbreviations: PFS- progression free survival 
Sources: Clinical study report 
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Applicability tables 
 
Table A10: Summary table characterising the applicability of a body of studies 
Domain Description of applicability of evidence 
Population The population of the RESORCE trial was highly selected. The inclusion was restricted to 
those who tolerated sorafenib treatment defined as not less than 20 days at a minimum 
daily dose of 400 mg QD within the last 28 days prior to withdrawal and to those with a 
well-preserved general state and liver fonction (ECOG 0-1; Child-Pugh A). Hence, the 
population included in the RESORCE trial represents only a subgroup of the scoped 
population.  
Overall, given the highly selected population of the RESORCE trial, external validity of the 
trial is limited. 
Intervention The mode of administration, dosing and frequency of cycles used for regorafenib is 
consistent with the upcoming approved licence. 
Patients received study treatment until disease progression, unacceptable toxicity, or   
withdrawal of consent. This is in line with treatment recommendations.  
All patients received supportive care if indicated as it is done in clinical practice. 
Comparators Currently, no active drug is recommended and/or used in clinical practice for the treatment 
of patients with HCC who have been previously treated with sorafenib, and patients are 
commonly treated with BSC. BSC in cancer may include assessment and treatment of 
physical, psychological, social, and spiritual dimensions of suffering.  
 
The appropriateness of BSC as comparator is further supported by clinical practice guide-
lines from various scientific organizations (EASL-EORTC (24), ESMO-ESDO (25), NCCN 
(26), and LAASL (27). No issue regarding intervention applicability was identified 
Outcomes There is evidence regarding OS and clinical benefits that support OS have been 
demonstrated. 
Clear limitation related to applicability of the results in terms of outcomes is the lack of 
interpretable HRQoL data. 
Given the highly selected population of the RESORCE trial, there is an indirectness issue.  
Setting The RESORCE trial is a multicentre study with approximately 38% of the subjects from 
Asia and approximately 62% of subjects from the ROW. No issue regarding setting 
applicability was identified. 
Abbreviations: ROW=rest of the world. 
Sources: Clinical study report and MAH submission file. 
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APPENDIX 2: REGULATORY AND REIMBURSEMENT STATUS 
Table A11: Regulatory status 
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Regorafenib 
EU 
central 
procedure 
EMA Yes  STIVARGA® 
is indicated as 
monotherapy 
in adult 
patients with 
hepatocellular 
carcinoma 
(HCC) who 
have been 
previously 
treated with 
sorafenib. 
August 2, 
2017 
Full, 
indication 
extension 
Septembe
r 2017 
EU/1/13/85
8 
USA FDA Yes STIVARGA® 
is indicated in 
patients with 
hepatocellular 
carcinoma 
(HCC) who 
have been 
previously 
treated with 
sorafenib. 
April 27, 
2017 
Full, 
indication 
extension 
April 27, 
2017 
NDA 
203085 
Ecuador Ecuador 
drug 
regulator 
agency 
Yes STIVARGA® 
is indicated for 
the treatment 
of patients 
with 
hepatocellular 
carcinoma 
(HCC) who 
have been 
previously 
treated with 
one systemic 
therapy. 
April 24,  
2017 
Full July,  
2017 
 
Japan PMDA Yes STIVARGA® 
is indicated in 
unresectable 
hepatocellular 
carcinoma 
progressed 
after treatment 
with cancer 
chemotherapy
. 
June 26, 
2017 
Full June 26, 
2017 
 
Korea MFDS Yes STIVARGA®  
is indicated in  
patients in 
hepatocellular 
July 12, 
2017 
Full July 12, 
2017 
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carcinoma 
(HCC) who 
have been 
previously 
treated with 
sorafenib 
Switzerlan
d  
Swissmedi
c 
No / / / / / 
Comparator technology: there is no active comparator 
Not 
applicable 
Not 
applicable 
Not 
applicabl
e 
Not applicable Not 
applicabl
e 
Not 
applicabl
e 
Not 
applicable 
Not 
applicable 
 
Abbreviations: EMA=European Medicines Agency; FDA=Food and Drug Administration; MFDS=Ministry Of Food and 
Drug Safety; PMDA=Pharmaceuticals and Medical Devices Agency. 
Sources: Manufacturer’s submission file and public information for regulatory agencies. 
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Table A12: Summary of (reimbursement) recommendations in European countries for the 
technology 
Country and  
issuing 
organisation 
e.g., G-BA, NICE 
Reimbursement 
status (Y, N, 
Ongoing) 
Summary of 
(reimbursement)  
recommendations and 
restrictions 
Summary of reasons for 
recommendations, 
rejections and restrictions 
Technology 
Austria Y Positive for both mCRC and 
GIST indication 
 
Belgium Y Positive for both mCRC and 
GIST indication 
 
Bulgaria Ongoing Ongoing for both mCRC and 
GIST indication 
 
Croatia N Negative for both mCRC and 
GIST indication 
 
Cyprus Y Positive for both mCRC and 
GIST indication 
 
Czech Republic Y, N Postive for mCRC and 
negative for GIST indication 
 
Denmark Y Positive for both mCRC and 
GIST indication 
 
Estonia N Negative for both mCRC and 
GIST indication 
 
Finland Y Positive for both mCRC and 
GIST indication 
 
France Y Positive for both mCRC and 
GIST indication 
Recommendation for 
reimbursement in mCRC is 
limited to patients with ECOG 
0-1 
Germany N Negative for both mCRC and 
GIST indication 
 
Greece Y Positive for both mCRC and 
GIST indication 
 
Hungary Ongoing Ongoing for both mCRC and 
GIST indication 
 
Ireland Y Positive for both mCRC and 
GIST indication 
 
Italy Y Positive for both mCRC and 
GIST indication 
 
Latvia N Negative for both mCRC and 
GIST indication 
 
Lithuania N Negative for both mCRC and 
GIST indication 
 
Luxembourg Y Positive for both mCRC and 
GIST indication 
 
Malta N Negative for both mCRC and 
GIST indication 
 
Netherlands Y Positive for both mCRC and 
GIST indication 
 
Norway Ongoing Ongoing for both mCRC and 
GIST indication 
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Country and  
issuing 
organisation 
e.g., G-BA, NICE 
Reimbursement 
status (Y, N, 
Ongoing) 
Summary of 
(reimbursement)  
recommendations and 
restrictions 
Summary of reasons for 
recommendations, 
rejections and restrictions 
Poland N Negative for both mCRC and 
GIST indication 
 
Portugal N, Ongoing Negative for mCRC and 
ongoing for GIST indication 
 
Romania N Negative for both mCRC and 
GIST indication 
 
Slovakia N Negative for both mCRC and 
GIST indication 
 
Slovenia N Negative for both mCRC and 
GIST indication 
 
Spain Y Positive for both mCRC and 
GIST indication 
 
Sweden Y Positive for both mCRC and 
GIST indication 
 
Switzerland Y Positive for both mCRC and 
GIST indication 
 
United Kingdom N, Y Negative for mCRC and 
positive for GIST indication 
 
Comparator: there is no active comparator -  not applicable 
    
For countries with indication specific reimbursement include only the recommendations for the 
indication under assessment. 
Include a reference to any publically available guidance document 
Abbreviations: GIST=gastrointestinal stromal tumours; mCRC=metastatic colorectal cancer; N=no; Y=yes. 
Source: Manufacturer’s submission file. 
 
Table: Benefit assessment based on original ESMO-MCBS and adapted benefit assessment based on adapted ESMO-MCBS  
ESMO-
MCBS 
Active  
substance Indication Intention PE Form 
MG standard 
treatment 
Efficacy Safety 
AJ FM 
MG months 
HR 
(95% CI) 
Score calculation PM Toxicity QoL 
Adapted 
ESMO-
MCBS 
Regorafenib HCC NC OS 2a ≤12 months +2.8 
0.63  
0.5-0.79 
HR ≤0.65 AND Gain ≥2.0  
<3 months 
3 
+34.3% grade 
3–4 AEs1, 
+6% DR 
no 
difference 
-1 2 
Original 
ESMO-
MCBS 
Regorafenib HCC NC OS 2a ≤12 months +2.8 
0.63  
0.5-0.79 
HR ≤0.65 AND Gain ≥2.0  
<3 months 
3 x 
no 
difference 
x 3 
Abbreviations: AEs = adverse events, AJ = Adjustments, CI = confidence interval, DR = discontinued due to adverse events, FM = final adjusted magnitude of clinical benefit grade, HCC = hepatocellular carcinoma, HR = hazard ratio, 
MG = median gain, NC = non-curative, OS = overall survival, PE = primary endpoint, PM = preliminary magnitude of clinical benefit grade, QoL = quality of life 
 
DISCLAIMER 
The scores achieved with the ESMO Magnitude of Clinical Benefit Scale are influenced by several factors: by the specific evaluation form used, by the confidence interval (CI) of the endpoint of interest, and by score 
adjustments due to safety issues. Ad form: Every individual form measures a different outcome. The meaning of a score generated by form 2a is not comparable to the exact same score resulting from the use of form 2c. To 
ensure comparability, we report the form that was used for the assessment. Ad CI: The use of the lower limit of the CI systematically favours drugs with a higher degree of uncertainty (broad CI). Hence, we decided to avoid 
this systematic bias and use the mean estimate of effect. Ad score adjustments: Cut-off values and outcomes that lead to an up- or downgrading seem to be arbitrary. In addition, they are independent of the primary 
outcome and, therefore, a reason for confounding. Hence, we report the adjustments separately. 
 
 
 
                                                          
1
 downgrade due to a difference of at least 10% in grade ≥3 AEs (+34.3) 
